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2 INTRODUCTION 
2 2 Introduction 
2.1 Background and aim of the study 
 
The liver-resident Kupffer cells play an important role in inflammatory liver 
signalling. Exposure to pathogens like bacteria and viruses, as well as diverse hepatic 
disorders such as ischemia/reperfusion injury and alcoholic liver disease, lead to an 
activation of the redox-sensitive transcription factor Nuclear Factor κB (NF-κB). As 
a consequence, proinflammatory chemokines and cytokines like Tumor necrosis 
factor α (TNF-α) are produced and released. However, the effect of NF-κB in liver 
tissue is highly cell-type specific. Whereas exceeding NF-κB activation in Kupffer 
cells is associated with liver inflammation, NF-κB in hepatocytes acts in a protective 
manner by the transcription of antiapoptotic genes. A global inhibition of hepatic 
NF-κB, irrespective of the cell type targeted was shown to increase TNF-α mediated 
apoptosis (1), to impair liver regeneration after partial hepatectomy (2) and to 
enhance injury after hepatic ischemia/reperfusion (3). Consequently, a universal 
hepatic inhibition of NF-κB is not a therapeutic option, which makes the need for a 
selective targeting of NF-κB in Kupffer cells obvious. 
Thus, the aim of this study can be outlined as follows: 
 
1. Development of a specific carrier in order to deliver NF-κB binding decoy 
oligodeoxynucleotides selectively to the resident liver macrophages. To this end, 
solid gelatin nanoparticles were loaded with fluorescent NF-κB decoy 
oligodeoxynucleotides and the biodistribution was examined by confocal 
microscopy. 
 
2. Providing the proof of principle for a selective NF-κB-targeting in Kupffer cells. 
Therefore, the influence of NF-κB decoy nanoparticles on lipopolysaccharide (LPS) 
challenged liver tissue in vivo was evaluated. 
 
Introduction 3 
3. Investigation of the impact of a selective NF-κB inhibition in Kupffer cells on in 
vivo hepatic ischemia/reperfusion (IR) injury. For this purpose, the model of partial 
warm IR in rats was established in our group and decoy nanoparticles were 
administered before the induction of 70% liver ischemia, in order to compare the 
outcome to untreated animals. 
 
2.2 Kupffer cells 
 
The liver consists of both parenchymal (i.e. hepatocytes) and non-parenchymal cells 
(i.e. Kupffer cells, endothelial cells, and Ito or hepatic stellate cells). Hepatocytes 
account for up to 60% of liver cells and 90% of liver mass and are responsible for 
maintaining liver function, mainly metabolism, bile production and drug 
detoxification (4). Kupffer cells, contributing to 15% of liver cells and less than 3% 
of liver mass, are the largest population of resident macrophages in the body. Due to 
their strategic position within the liver sinusoids (Figure 1), Kupffer cells are the first 
macrophage cell type to come in contact with pathogens and microbial products, thus 
forming the primary line of host defense. They are actively phagocytic and represent 
an important cellular system for removal of particulate materials and microbes from 
the circulation. Their location just downstream from the portal vein allows Kupffer 
cells to efficiently scavenge bacteria that reach the blood flow of the portal veins 
through disruptions in the intestinal epithelium, thus preventing invasion of the 
systemic circulation. Rapidly after exposure to foreign bodies like viruses and 
bacteria, Kupffer cells produce and release a variety of proinflammatory cytokines 
and other agents necessary for the elimination of these pathogens (5;6), such as 
TNF-α, Interleukin (IL)-6, -12 and -1β, as well as nitrice oxide, reactive oxygen 
species (ROS) and chemokines like MIP-1 and -2 (6). Subsequently, microbicidal 
neutrophils are recruited to the activated Kupffer cells and immigrate rapidly in 
response to infection (7). Among these cytokines released, TNFα is one important 
member opposing the pathogenic threat. However, overexpression of TNFα leads to 
diminished hepatocyte viability and to increased liver damage (8;9). 
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Figure 1 Localization of a Kupffer cell within the liver sinusoid (scanning electron microscopy 
image taken from Naito et al. (10)). 
Kupffer cells play an important role in the pathogenesis of various liver diseases. 
During fibrosis, Kupffer cells release different cytokines like TGF-β1, which in turn 
activates the hepatic stellate cells, the cell type mainly responsible for liver fibrosis 
(11). Alcohol-related liver disease is a chronic inflammatory disease of the liver 
parenchyma. Acute or chronic ethanol administration causes an increase in numbers 
of Kupffer cells and therefore brings about an enhanced production of inflammatory 
mediators such as IL-1, TNF-α and oxygen free radicals (11). In addition, ethanol 
ingestion seems to heighten the amount of gram negative bacteria in the bowel flora. 
Followed by a rise in the intestinal permeability, higher levels of LPS can be found 
in the portal vein, which subsequently activates the Kupffer cells (11). 
Furthermore, Kupffer cell activity is found to be increased soon during postischemic 
reperfusion injury, which will be discussed in further detail below. 
Moreover, Kupffer cells are important regulators for liver regeneration. The liver 
differs from the other interior organs due to its unique capability to restore its 
original mass, even after 70% of tissue extraction. Soon after resection, mediators 
like TNF-α and IL-6 are released by the liver macrophages, which primes 
hepatocytes to proliferate. The crucial role of Kupffer cells in this context is further 
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emphasized by the fact that depletion of the liver macrophages leads to diminished 
regeneration and proliferation (12). 
Inhibition of Kupffer cell action can be achieved by different methods. 
Administration of the rare earth metal gadolinium (as gadolinium chloride) leads to 
Kupffer cell depletion within 24 hours, probably by exchange with Ca2+ ions and 
interaction with Ca2+ dependent processes. Liposomal encapsulated clodronate is 
taken up selectively by the liver macrophages and destroys Kupffer cells upon 
intracellular release. The fatty acid derivative methylpalmitate is thought to integrate 
into the cell membrane, which results in membrane breakdown. Furthermore, 
selective inhibition of Kupffer cell activity has been reported by the use of glycine 
(13). 
Though Kupffer cell depletion has shown beneficial effects in various experimental 
inflammatory models (14;15), complete elimination of this important cell type from 
the liver is not a therapeutic option, since Kupffer cells are indispensable for intact 
immune function (16). In addition, several side effects like toxicity of gadolinium 
chloride on hepatocytes limit the use of Kupffer cell depleting agents. 
2.3 NF-κB 
 
2.3.1 General aspects 
 
The redox-sensitive transcription factor NF-κB displays pleiotropic effects during 
inflammation, immune response, cell survival and proliferation (17). 
Five members of the mammalian NF-κB family have been described so far – p50, 
p52, p65/RelA, p68/RelB, and p75/c-Rel (18-20). Inactive NF-κB is sequestered in 
the cytoplasm, where it is bound to its inhibitory protein IκB, which prevents 
translocation to the nucleus. Upon stimulation, like endotoxemia and TNF-α 
challenge, the upstream kinase IκB kinase (IKK) is phosphorylated (Figure 2), which 
in turn facilitates phosphorylation of the inhibitory protein IκB associated with 
NF-κB. After degradation of IκB by the 26S-proteasome, NF-κB is released from its 
cytoplasmic retention and translocates to the nucleus (20-22). In the nucleus, several 
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costimulating processes like acetylation by histone acetyltransferases (HAT) and 
phosphorylation are needed to enable NF-κB transcriptional activity. 
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Figure 2 Classical pathway of NF-κB induction 
However, other activation cascades of NF-κB occur as well. An alternative pathway 
is exclusively triggered by IKKα homodimers which results in a selective activation 
of p52/RelB heterodimers (23). Furthermore, in ischemia and reperfusion, the 
heterodimer p50/p65 translocates to the nucleus without previous ubiquitination and 
degradation of IκB (24). In summary, increasing evidence emerged that induction of 
NF-κB transcriptional activity is regulated at multiple levels, depending on the 
stimulus investigated. 
NF-κB is mainly involved in B and T cell development under physiological 
conditions (25) and is a central mediator of the mammalian immune response. Many 
stimuli can rapidly activate NF-κB leading to the expression of various genes, 
basically cytokines, chemokines, cell adhesion molecules, stress response genes, 
growth factors and antiapoptotic regulators (20). NF-κB activity is upregulated in 
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many pathological conditions. As a key regulator of cytokine expression, NF-κB 
induction is a central event in inflammatory processes. Therefore it is not surprising 
to find NF-κB levels elevated in incidents like artherosclerosis, allergy and heart 
diseases (25). 
The cytokine TNF-α is a prominent member of NF-κB target genes. Being a 
necessary mediator for immune host defense, TNF-α is involved in most NF-κB 
regulated responses. However, exceeding release of TNF-α is linked to excessive 
inflammation and cell damage. In addition, TNF-α itself stimulates NF-κB 
translocation, creating a positive feed-back loop. Therefore, duration and dimension 
of TNF-α secretion is a decisive factor for the extent of inflammation (26). 
 
2.3.2 NF-κB in the liver 
 
The role of NF-κB in liver tissue is highly cell-type specific (Figure 3). Activation of 
NF-κB in the resident liver macrophages upon inflammatory stimuli causes increased 
expression of proinflammatory cytokines, which leads to inflammation and liver 
failure (27;28). Kupffer cells are thought to be the main source of TNF-α in the liver, 
and TNF-α gene transcription is strongly regulated by NF-κB (29). This predestines 
NF-κB as a promising target for antiinflammatory therapy. Induction of NF-κB 
activity in hepatocytes however is linked to cellular protection by increasing the 
transcription of antiapoptotic genes (30). Therefore, a systemic inhibition of NF-κB 
in the liver for suppression of hepatic inflammation is not feasible, as this results in 
increased hepatocyte apoptosis (1). The dual role of NF-κB in the liver is further 
underlined by the fact that p65 knock-out mice die during embryogenesis due to 
massive hepatocyte apoptosis (31). 
NF-κB is also an essential factor for liver regeneration. After partial liver resection, 
NF-κB is activated in Kupffer cells as well as in hepatocytes, thus triggering cell 
proliferation. An increase of liver macrophage NF-κB effects a release of mitogens 
like IL-6 (32), which in turn acitvates NF-κB in heptocytes (33). Subsequently, 
hepatocytes enter the cell cycle. Selective inhibition of NF-κB in hepatocytes entails 
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increased apoptosis and diminished proliferation after partial hepatectomy (34), and 
inhibition of NF-κB in Kupffer cells reduces liver regeneration capacity as well (2). 
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Figure 3 Cell-type dependent effects of NF-κB activation 
 
In the light of the beneficial and antiapoptotic properties of NF-κB in hepatocytes, 
the requirement for a Kupffer cell selective inhibition of NF-κB is obvious (8;35). 
 
2.3.3 NF-κB inhibitors 
 
There is currently an abundance of more or less specific NF-κB inhibitors available, 
interacting with the NF-κB activation cascade at numerous sites (36;37). Being a 
redox-sensitive transcription factor, a multitude of antioxidants is utilized, in 
particular gluthation, N-acteyl-cysteine (NAC) and pyrrolidinedithiocarbamate 
(PDTC). Several medicinal drugs like aspirine, ibuprofen and sulfasalazine inhibit 
phosphorylation of the inhibitory protein IκBα, thus preventing its displacement from 
the cytoplasmatically retained NF-κB. As IκBα is degraded by ubiquitination, 
proteasome inhibitors like cyclosporin and tacrolimus inhibit NF-κB translocation as 
well. Other inhibitors act at the nuclear stage, for instance by hindering nuclear 
transport (leptomycin B) or by interacting with acetylation processes of NF-κB 
Introduction 9 
(glucocorticoids). However, an interaction of these molecules with other targets and 
therefore various side effects by their use can not be ruled out. 
IκB as the regulatory switch displays a logical target for inhibition, and 
overexpression of IκB (38) has been tested. But these approaches are time-
consuming and safety issues remain a key problem.  
There are at least four different IKK inhibitors currently in clinical trials. As an 
important upstream activator of NF-κB signalling, interference with the IKK-cascade 
seems a promising approach for anti-inflammatory treatment. However, long-term 
studies are still missing and especially side effects like teratogenicity and 
susceptibility to infections could present major limitations for the therapeutic use 
(39). Moreover, recent studies revealed that hepatocyte-specific deletion of the 
NEMO-subunit caused hepatocellular carcinoma in 12 month old mice (40). 
Although all tested IKK-inhibitors basically target IKK2, further investigations will 
be needed to rule out any cross-reactions. 
Thus, there is still a need for the development of more specific NF-κB inhibitors with 
less occurring side effects. 
 
2.4 Decoy oligodeoxynucleotides 
 
A more suitable tool for interacting with transcription factors like NF-κB is the 
double-stranded NF-κB decoy oligodeoxynucleotides (ODNs) corresponding to the 
promoter sequence, as imprecise interactions are less likely to occur due to the 
specific binding of the transcription factor to decoy oligonucleotides. 
A transcription factor translocates to the nucleus after stimulation and activation, 
where it binds to the so called promoter region of its particular gene. The promoter 
region contains the consensus sequence, a highly specific order of base pairs that is 
recognized by the transcription factor. The subunits p50 and p65 for instance 
associate to a five (GGGAC) and a four (TTCC) base-pair consensus-sequence, 
respectively. 
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Transfection of double-stranded oligonucleotides leads to competitive cis-trans 
interactions between oligonucleotides and the transcription factor, thus preventing 
binding of the transcription factor to the designated genomic DNA (41). The cell is 
actually flooded with these short DNA-strands, and the transcription factor can not 
distinguish between the artificial binding sites in the cytoplasm and the original locus 
in the nucleus. The advantage of using decoy oligonucleotides lies in the specificity 
of the binding and therefore in the mode of inhibition. As the consensus-sequence is 
only recognized by the predestined transcription factor, unwanted side effects can be 
ruled out. 
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Figure 4 Model of decoy-transcription factor interaction 
The utilization of NF-κB decoys (42;43) has been shown to have beneficial effects in 
the models of renal ischemia/reperfusion injury (44), hepatic metastasis of murine 
reticulosarcoma (45) and neuronal damage after brain ischemia (46). 
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2.5 Carriers 
 
Under physiological conditions, decoy oligonucleotides are negatively loaded. 
Hence, a passage through the lipophilic cell membrane is almost impossible. 
Transfection of oligonucleotides into cells takes place only at very low transfection 
rates. Therefore, a potent carrier has to be used to transport the decoys to the target 
cells. As binding of decoy oligonucleotides to the transcription factor occurs in a 
dose-dependent manner, sufficient delivery to the cytoplasm is of utmost importance. 
 
2.5.1 Targeting of Kupffer cells 
 
Kupffer cells are the largest resident macrophage population in the body and are 
located within the liver sinusoids. Thus, they come in contact with every particle in 
the hepatic blood circulation. As Kupffer cells have a high phagocytic activity, many 
carriers are taken up by these macrophages, and numerous studies were conducted on 
avoiding Kupffer cell incorporation. However, for an exclusive targeting of Kupffer 
cells without affecting other cell types in vivo, a modification of carriers for specific 
delivery is necessary. 
Kupffer cells possess sugar derivatives recognizing receptors on the outside 
membrane. Hence, carriers provided with mannose and fucose residues on their 
surface are reported to be taken up at higher rates (47). This is basically practiced in 
conjunction with liposomal carriers. Liposomes are vesicular colloid particles 
composed of self-assembled amphiphilic molecules (48). Molecules to be delivered 
can be encapsulated into the interior or bound on the surface of the liposomes, which 
are taken up by cells either by endocytosis or by fusion of the lipophilic cell 
membranes with the liposomal outside layer (49). Incorporation of the 
hemagglutinating virus of Japan (HVJ) components into liposomes results in further 
enhanced Kupffer cell uptake. However, mode of administration in this context 
seems to be of great importance, as application by intravenous injection causes lower 
Kupffer cell transfection than direct intraportal infusion (50). 
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Moreover, coupling of substances to low-density lipoprotein (51) and to serum 
albumin (52) are additional alternatives for Kupffer cell targeting, but a noticeable 
portion of applied material is transported to endothelial cells as well. 
Adenoviral gene transfer is often used as vector for gene delivery. However, 
administration of an adenoviral vector resulted in an higher inflammatory response of 
Kupffer cells (53), an effect that has been reported to a lower extent for 
nanoparticulate carriers as well (54). 
 
2.5.2 Carriers for oligonucleotides 
 
Oligonucleotides used as decoys or as antisense nucleotides are useful tools for 
interacting with cellular processes. Nevertheless, selective delivery of 
oligonucleotides remains a key problem, and the search for carriers that fulfill this 
requirement has been intensified. Liposomes and nanoparticles have emerged as the 
most suited ones for the delivery of oligonucleotides. Both lie within in the same size 
range from 10 to 1,000 nm and belong to the colloidal dispers systems. Fluid-type 
liposomes have turned up as the state-of-the-art carrier for the delivery of 
oligonucleotides (49), as they provide for easy and sufficient delivery of incorporated 
oligonucleotides to cells. However, directed targeting of liposomes to certain cell 
types is not possible without deeper modifications, because liposomes tend to fuse 
with all kinds of cells. Nanoparticles have to be taken up by endocytosis, which 
leaves phagocytic competent cells as main targets. Upon intravenous administration, 
nanoparticles are rapidly cleared from the circulation through phagocytosis, 
preferentially by macrophages of the reticuloendothelial system (RES) concentrating 
mainly in liver and spleen (55). Nanoparticles can be manufactured from 
biodegradable polymers, for example polylactic acid, polyglycolic acid and chitosan 
(56), and they have been shown to be more efficient drug carriers than liposomes due 
to their better stability and lower toxicity (57). 
The oligonucleotides are either covalently or reversibly bound to the nanoparticle 
surface. After endocytosis, oligonucleotides have to be released from the lysosomal 
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compartment, which can present a major limitation for exerting a biological effect 
(57). 
 
2.5.3 Gelatin nanoparticles 
 
A pronounced uptake into Kupffer cells of surface-modified liposomes has been 
described (47;49;50), but also a relevant delivery to hepatocytes could not be 
eliminated (58). Therefore, a tool for the selective targeting of Kupffer cells with 
oligonucleotides has not been developed so far. This prompted us to evaluate if a 
nanoparticulate carrier composed of gelatin can be used for the delivery of NF-κB 
decoy oligonucleotides to Kupffer cells. Solid nanoparticles display advantages over 
the use of liposomes because of their higher stability, lower toxicity and better 
efficiency in drug delivery (57). 
Gelatin is a well known biodegradable protein with low immunogenic properties and 
displays a safe and non-toxic material, as it is widely used in medicine as ingredient 
in various plasma expanders. It is a natural macromolecule that can be easily 
obtained by heat dissolution and partial hydrolysis of collagen in animal skins, bones 
and tendons. 
Nanoparticles made from gelatin were first described in 1978 (59) and their 
manufacture has been improved steadily ever since (60). They offer the advantages 
of a simple and safe delivery system, and nanoparticles consisting of a solid gelatin 
core have been proven to be a well suited carrier system for double stranded 
oligonucleotides. By introducing positive charges on the surface of the gelatin 
nanoparticles, negatively charged nucleotides can be stably loaded onto the particles 
due to ionic interactions (61;62). Unmodified gelatin nanoparticles have already been 
reported to be taken up by dendritic cells (63) and B16 F10 mouse melanoma cells 
(62) in vitro. 
The exact manufacturing protocol and characteristic properties of the nanoparticles 
used in this study are described by Jan Zillies in his PhD thesis from 2007. 
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2.6 LPS 
 
The glycolipid lipopolysaccharide (LPS) is a component of the outer membrane of 
gram-negative bacteria and has the ability to evoke a strong inflammatory response. 
The liver is a final barrier that hinders gut-derived LPS from entering the circulation, 
thus playing an important role in clearing LPS from the systemic blood stream (64).  
Upon contact of the endotoxin with a LPS-recognition receptor expressed on the cell-
surface, the so called Toll-like receptor (TLR) 4, an intracellular cascade is initiated. 
With the participation of various cofactors, the IKK-activity is ultimately induced, 
which leads directly to an activation of NF-κB (17;64). 
After systemic LPS challenge, the mRNA expression of various cyokines like TNF-α 
are soon upregulated, and the rise in mRNA levels correlates with the status of 
NF-κB activation. Inhibition of NF-κB by PDTC for instance, abolished LPS 
induced cytokine and chemokine expression (65). 
Due to their location in the liver sinusoids, Kupffer cells are among the first cell 
types to be exposed to LPS from the intestine. This fact, in addition to their high 
phagocytic activity makes them the most important scavenger for circulating 
endotoxin. Depletion of Kupffer cells with gadolinium chloride lead to an increased 
survival with diminished cytokine release (66), pointing to the significance of the 
resident liver macrophages in LPS clearance.  
Kupffer cells are the most prominent members of the liver cell population to generate 
TNF-α. Stimulation of isolated hepatocytes with LPS is not able to provoke a release 
of TNF-α, unless a co-culture model together with Kupffer cells is employed (67). 
Hepatocytes alone are not susceptible to LPS triggered apoptosis, but adding the 
supernatant of LPS-challenged Kupffer cells to the hepatocyte cell culture enhances 
liver cell death (68). Due to this relevance of Kupffer cells in mediating LPS induced 
TNF-α release, NF-κB as central modulator of TNF-α gene transcription in Kupffer 
cells becomes an apparent target for intervention. 
The groups of Ogushi and Higuchi respectively (69;70) addressed this issue and used 
modified liposomal carriers (hemagglutinating virus of Japan (HVJ-) liposomes as 
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well as mannosylated cationic liposomes) to transfect Kupffer cells with NF-κB 
decoy oligonucleotides. Indeed, NF-κB-inhibition in LPS-treated mice showed a 
positive effect on cytokine expression and mouse survival. However, liposomal 
carriers are not an appropriate tool for targeting Kupffer cells alone, as other liver 
cells are affected as well. 
 
2.7 Hepatic ischemia/reperfusion injury 
 
2.7.1 General mechanisms 
 
Ischemia/reperfusion (IR) injury is still a major cause for problems during liver 
transplantation and resection and accounts for up to 20% of liver transplant failures. 
There are two different models of hepatic IR in vivo, which are distinguished by the 
way of storage during the ischemic period. Warm IR (also named Pringle 
manoeuvre) is often used in clinical situations when surgical intervention on hepatic 
tissue is needed to prevent excessive bleeding, like liver resection. Warm IR is 
characterized by an overbalance of hepatocyte damage to non-parenchymal cell 
injury (71). Cold IR occurs mainly during transplantation procedures, as the 
harvested organ has to be delivered to the recipient. This transportation period can 
last for up to several hours, and to ensure the best possible organ quality, the liver is 
stored at 4°C in the so called University of Wisconsin (UW) solution. 
While the manifestation of the actual damage is thought to occur with the onset of 
reperfusion, the basic deterioration begins during the ischemic period, and prolonged 
ischemia times correlate with poorer outcome of organ preservation. Soon after 
disconnection from the blood stream, the loss of mitochondrial respiration due to the 
lack of oxygen leads to ATP depletion and a subsequent deterioration of energy-
dependent pathways (72). Thereupon, anaerobic processes lead to a shift of cellular 
pH towards acidosis (73). To reduce the metabolic rates, which enables anoxic cells 
to maintain essential metabolic functions for a longer time period, organs for liver 
transplantations are initially cooled down and kept on ice for transportation. During 
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warm ischemia, where the organ is held at normal body temperature, a further 
important stimulus for organ damage during the ischemic period is given by the 
increased activities of non-lysosomal proteases (72). 
The amplification of liver damage in the reperfusion period can be divided into two 
distinct phases, an immediate (or acute) and a late (subacute) phase. The initial 
period (<2 h after reperfusion) is characterized by oxidant stress. The late phase of 
liver injury from 6 to 48 h after hepatic reperfusion is an inflammatory response 
mediated by infiltrating neutrophils (73). 
 
Ischemia/reperfusion
Kupffer cell activation
ROS
Inflammatory cytokines
(TNF-α, IL)
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Leukocyte – Endothelial cell
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Complement activationCD4+ T-cell activation
ROS
 
Figure 5 Schematic illustration of the pathophysiology of liver ischemia/reperfusion injury 
After initiation of reperfusion the liver is overwhelmed by the large amount of 
oxygen. Due to their strategic position in the liver sinusoids, Kupffer cells react fast 
after the sudden onset of blood and therefore oxygen supply (Figure 5). Reactive 
oxygen species (ROS) are considered to be produced by Kupffer cells within few 
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minutes, which subsequently triggers production and release of a plethora of 
cytokines like TNF-α and IL-1 (74). Moreover, ROS can have direct cytotoxic 
effects on hepatocytes. The released cytokines induce endothelial cells to express 
adhesion molecules like Intercellular Adhesion Molecule (ICAM)-1 and E-selectin 
on their cell surface. This marks the beginning of the late phase of IR injury, which is 
characterized by the interaction of endothelial cell adhesion molecules with their 
counterparts on circulating neutrophils (74). In addition, release of chemokines like 
cytokine-induced neutrophil chemoattractant (CINC) and macrophage inflammatory 
proteins (MIP)-1 and-2 contribute to neutrophil recruitment to the injured tissue. 
After contact of neutrophils with endothelial cells and aggravation of adhesion, the 
recruited neutrophils begin to extravasate to the parenchyma. Adherence to 
hepatocytes finally leads to degranulation, subsequent protease release and a long-
lasting oxidant stress, resulting in parenchymal injury. In addition, neutrophils 
attached to endothelial cells form an obstacle within the sinusoids, which is 
associated with a decline in blood flow and therefore microcirculatory failure (75). 
The radical NO is synthesized by the enzyme NO synthetase (NOS). There exist two 
isoforms of NOS in the liver, endothelial NOS (eNOS) and inducible NOS (iNOS). 
The role of NO formation during IR is very controversial. NO radicals can be 
converted to peroxynitrite by reaction with the ROS superoxide. Peroxynitrite itself 
is cytotoxic by exerting different effects, e.g. lipid peroxidation. Therefore, inhibition 
of NO formation should ameliorate hepatic IR injury. On the other hand, NO is 
necessary for maintaining liver blood flow. Several studies have been conducted for 
elucidating the role of NO in IR injury. However, detrimental as well as beneficial 
effects of NO have been reported, which is thoroughly discussed by Jaeschke (74). 
Many insights into the role of Kupffer cells for ischemia/reperfusion injury were 
obtained through studies with depleted Kupffer cells. As described in chapter 2.2 
various methods for eliminating the resident liver macrophages exist. Depletion of 
Kupffer cells has been shown to ameliorate warm hepatic ischemia/reperfusion 
injury, as demonstrated by reduction of transaminase levels (76), diminished CINC 
release and neutrophil infiltration (77), reduced TNF-α plasma levels (78) and by 
increased survival after 1 hour of total hepatic ischemia (79). However, Kupffer cells 
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seem to be indispensable for liver regeneration, as their elimination delays liver 
regeneration (80) and decreases the survival rate after partial hepatectomy (81). 
In summary, Kupffer cells possess a key role in the signalling events leading to 
ischemia/reperfusion injury, but are also essential for liver regeneration. 
 
2.7.2 Role of NF-κB 
 
ROS play a crucial role in the initial period of postischemic reperfusion injury. 
Hence, being a redox-sensitive transcription factor, hepatic NF-κB levels are 
increased soon after the beginning of the reperfusion period (82;83). However, 
evidence emerged that the NF-κB activation cascade is likely to be triggered 
differently in hepatic ischemia/reperfusion (24). Phosphorylation of IκBα is normally 
executed on serines 32 and 36, for instance after TNF-α or LPS challenge. In the 
context of liver IR, IκBα is only phosphorylated on tyrosine 42. Fan et al (84) 
postulate that this activation scheme is occurring independently from the IKK-
complex, but rather relies on c-Src mediated phosphorylation. Consequently, IκBα is 
not targeted for ubiquitin mediated degradation by the proteasome, thus remaining 
undisrupted in the cytoplasm. 
The relevance of NF-κB in this context can be estimated by the fact, that suppression 
of NF-κB by antioxidants (85), radical scavengers (86) or NF-κB inhibitors (87) in 
fact decreased TNF-α release, transaminase levels and liver damage. Inactivation of 
NF-κB enhancing pathways, for instance by deletion of the upstream kinase IKK2 
(88) or by overexpression of inhibitory IκBα (38), abrogated IR induced increase in 
hepatocellular injury. However, as described in section 2.3.2, the dual role of NF-κB 
applies to the setting of hepatic ischemia/reperfusion as well. So it is not surprising to 
find reports indicating rather a protective role for NF-κB in liver IR (89;90). 
Recently, Lentsch and colleagues (91) were able to show that higher NF-κB levels in 
hepatocytes during IR are linked with protection, while an increase of NF-κB in 
Kupffer cells rather induces TNF-α release and liver damage. However, their studies 
were based on isolated parenchymal and non-parenchymal cells from livers that had 
experienced warm ischemia/reperfusion. An in vivo evaluation of this issue was not 
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possible so far due to a missing possibility for selective interference with NF-κB in 
Kupffer cells. 
 
2.7.3 Interventions 
 
Several approaches for improving the injury caused by postischemic reperfusion 
have been investigated. The following sections will just provide a short overview, as 
a detailed listing would go beyond the scope of this work. 
As production and release of ROS are central events in IR injury, many antioxidative 
interventions were tried, like thiol-containing compounds (as N-acteylcysteine or 
gluthathione), oxygen radicals scavenging enzymes (superoxide dismutase, catalase), 
lipoic acid and allopurinol (92). All these compounds have been reported to be 
efficacious in the treatment of reperfusion injury, but to date none of these strategies 
have found the way into routine clinical practice (93). 
Further pharmacological interventions include a plethora of molecules. Hormone 
preconditioning with the atrial natriuretic protein (ANP) produced positive results 
(94), as did the use of pentoxyfilline (as an inhibitor of TNF-α synthesis), 
cyclosporine (inhibition of neutrophil infiltration) and adenosine agonists (93). 
The most commonly used buffer for organ preservation is the University of Wisonsin 
(UW) solution. Storage of harvested livers in UW solution results in minimized cell 
swelling, inhibited ROS production and increased adenosine triphosphate repletion. 
Several studies have tried to specify the active ingredients. Apparently, the beneficial 
effects of the UW solution are provoked by the mixture of different compounds, as 
single components are not able to exert similar results (95). 
Today, the only powerful strategy used in clinical practice is ischemic 
preconditioning (IP), consisting of a brief period of ischemia followed by a short 
interval of reperfusion before the actual surgical procedure. Ischemic preconditioning 
is connected with increased organ survival and diminished tissue damage. The 
method of IP is easily applicable in clinical situations, which makes this intervention 
very attractive. The mechanisms leading to the amelioration of reperfusion injury 
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were thoroughly investigated, and many targets have been named like adenosine, 
heat shock proteins and nitric oxide (96). The controversy about NF-κB in the liver 
during IP continues. While some reports indicate that NF-κB levels in the 
postischemic reperfusion period are diminished (97), an increase in NF-κB activity 
was also detected (98), which emphasises the contradictory and still unsettled role of 
NF-κB in the liver. Despite the growing number of reports investigating the 
mechanisms of hepatic protection by ischemic preconditioning, the present 
understanding of the ongoing processes is still of preliminary character (99). 
Generally it can be said that preconditioning with apparently damaging interventions 
like TNF-α seem to ameliorate reperfusion injury (100). 
Numerous interventions to improve the aftermath of postischemic liver damage have 
been subject of intensive research. However, not many interventions have found their 
way into everyday clinical situations, as the underlying mechanisms are still poorly 
understood. 
The transcription factor NF-κB might present a promising target for the treatment of 
hepatic ischemia/reperfusion injury. However, before using NF-κB inhibitors as 
drugs to prevent IR caused damage, the dual role of NF-κB in this context has to be 
evaluated in more detail. Hence, our aim was to utilize decoy nanoparticles as a tool 
for a selective downregulation of NF-κB in Kupffer cells, to clarify the function of 
this transcription factor in this liver cell type. 
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3.1 Materials and solutions 
Table 1 Materials 
Product Company 
Lipopolysaccaride (E.coli serotype 055:B05) Sigma-Aldrich, Taufkirchen, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
 
PBS pH 7.4  
  123.2  mM NaCl  
     3.16 mM KH2PO4  
    10.4  mM Na2HPO4  
 H2O  
 
3.2 Decoy oligodeoxynucleotides 
 
NF-κB decoy oligodeoxynucleotides (5’- AGT TGA GGG GAC TTT CCC AGG  
C -3’, 5’- GCC TGG GAA AGT CCC CTC AAC T -3’) and scrambled NF-κB decoy 
ODNs (5’- CCT TGT ACC ATT GTT AGC C -3’, 5’- GGC TAA CAA TGG TAC 
AAG G -3’) were obtained from Biomers, Ulm (biomers.net). Consensus sequences 
for p50 and p65 are underlined. For improved stability all ODNs were bridged with a 
phosphorothioate (PTO) backbone (57). Sequences for NF-κB decoy ODNs and 
scrambled decoy ODNs have been used elsewhere (101;102). For biodistribution 
studies cis-decoy ODNs were 5`-end-labeled with an Alexa Fluor® 488. 
 
 
 
Materials and methods 23 
3.3 Gelatin nanoparticles 
 
Preparation and loading of gelatin nanoparticles was done by Jan Zillies 
(Pharmaceutical Technology, Department of Pharmacy, University of Munich) and is 
described in more detail in his PhD thesis (2007). 
 
3.3.1 Materials 
Table 2 Materials used for gelatin nanoparticles preparation 
Product Company 
Acetone VWR, Ismaning, Germany 
Cholaminechloridehydrochloride Sigma-Aldrich Taufkirchen, Germany 
EDC Sigma-Aldrich, Taufkirchen, Germany 
Gelatin type A Sigma-Aldrich, Taufkirchen, Germany 
Glutaraldehyde Sigma-Aldrich, Taufkirchen, Germany 
HCl VWR, Ismaning, Germany 
Texas Red® sulfonyl chloride Invitrogen, Karlsruhe, Germany 
(scrambled) decoy oligonucleotides Biomers.net, Ulm, Germany 
Alexa Fluor® 488 end-labeled decoy 
oligonucleotides (NF-κB decoy ODN488) Biomers.net, Ulm, Germany 
 
3.3.2 Manufacture of decoy nanoparticles 
 
Gelatin nanoparticles were prepared by the two-step desolvation method as described 
previously (60). In brief, 1.25 g gelatin was dissolved in water (5% [w/w]) under 
stirring (500 rpm) and heating up to 50°C. The resulting solution was fractionated in 
a first desolvation step by quickly adding 25 ml of acetone. The remaining sediment 
was dissolved in 25 ml of water. Nanoparticles emerged in a second desolvation step 
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by dropwise adding 50 ml of acetone. After 5 min of stirring, the in situ formed 
particles were stabilized by crosslinking with 43.8 µg glutaraldehyde. The 
concentration of the nanoparticle dispersions was determined gravimetrically after 
purification by centrifugation and redispersion. 
Surface modification (cationization) of gelatin nanoparticles was performed with the 
quaternary amine cholamine in a modified procedure based on the method previously 
described by Coester (103): after preparation and purification, the nanoparticles were 
suspended in highly purified water and 50 mg cholamine were dissolved in the 
suspension. 50 mg EDC were added to the reaction vessel under constant stirring and 
the reaction was stopped after 3 h. 
Aqueous nanoparticle dispersions containing 0.85 mg or 0.73 mg surface modified 
gelatin nanoparticles were incubated with 120 µl aqueous oligonucleotide solution 
containing 6 nmol NF-κB decoy ODN or 6 nmol scr decoy ODN respectively (i.e., 
10% [w/w] drug loading) in a total volume of 1,200 µl highly purified water. For 
liver distribution studies equivalent amounts of fluorescent-labeled NF-κB decoy 
ODN488 were loaded onto the gelatin nanoparticles. Afterwards, sucrose was added 
in an excipient to oligonucleotide mass ratio of 200. The suspensions were 
freeze-dried in an EPSILON 2- 6D pilot scale freeze dryer from Martin Christ Freeze 
Dryers GmbH, Osterode, Germany. Rehydration was conducted directly before use 
in 169.8 µl and 146.3 µl respectively of highly purified water (leading to a 
concentration of 10% sucrose [w/v], which was almost isoosmotic) under adding a 
Tween® 80 solution (100 µg/µl) in a 1:1 ratio to the mass of gelatin nanoparticles. 
Finally, samples were completed with a 10% [w/v] sucrose solution to a total volume 
of 300 µl. Four samples were combined per animal study. Unloaded gelatin 
nanoparticles were accordingly treated. 
Size and zetapotential of the applied gelatin nanoparticle batches were determined by 
dynamic light scattering (DLS) using a Zetasizer 3000 HSA (Malvern Instruments, 
Worcestershire, UK). Zetapotential measurements were conducted under 
standardized ionic conditions in 10 mM NaCl at pH 7.0. 
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3.3.3 Preparation of fluorescent cationic gelatin nanoparticles 
 
Fluorescent labeled gelatin nanoparticles were prepared by covalent coupling of the 
gelatin base material with an amino reactive fluorescent dye. After the first 
desolvation step the remaining gelatine sediment was dissolved in 25 ml of water 
under constant stirring (500 U/min) and heating up to 50°C. 1 mg of the fluorescent 
dye (Texas Red®) was added to this solution after dissolving in acetone and the 
mixture was constantly stirred for 1 h (500 U/min) at 50°C. After this incubation 
period the regular gelatin nanoparticle manufacturing process was continued with the 
second desolvation step. Subsequent to purification, cationization was conducted as 
usual (see chapter 3.3.2). 
 
3.4 DOTAP/DOPC liposomes 
 
Drug loaded liposomes were prepared by ethanol injection with the oligonucleotide 
already present in the water phase. The chosen ODN lipid ratio is geared to the work 
of Ogushi who applied an NF-κB decoy oligonucleotide in a fatal liver failure murine 
model (69). 28.74 µl lipid ethanol stock solution (1.8 g DOTAP-Cl and 1.7 g DOPC 
in 10.0 g EtOH), were dropwise added into 1.5 ml aqueous oligonucleotide solution 
containing 15 nmol Alexa Fluor® 488 end-labeled NF-κB decoy ODN (i.e., 2% 
[w/w] drug loading) under constant stirring. The mixture was then 10x passed 
through a 0.22 µm sterile filter. This leads to a final volume of around 1.2 ml 
containing 12 nmol/ml NF-κB decoy ODN applicable for animal studies, equivalent 
to the sample volume of gelatin nanoparticle formulations. 
 
3.5 Cell culture 
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3.5.1 Materials 
Table 3 Materials and solutions used for cell culture 
Product Company 
Collagenase H Roche Diagnostics,Mannheim, Germany 
Dulbecco`s modified eagle medium 
(DMEM)    pH 7.0 – 7.5 
Cambrex Profarmaco, Landen, Belgium 
Fetal bovine serum (FBS) PAA Laboratories, Linz, Austria 
Neutral buffered formalin solution 10% Sigma-Aldrich, Taufkirchen, Germany 
L-Glutamine solution 200 mM Cambrex Profarmaco, Landen, Belgium 
Penicillin/Streptomycin (Pen/Strep) 
solution 
PAA Laboratories, Linz, Austria 
Trypsin solution PAA Laboratories, Linz, Austria 
Cell culture materials PESKE, Aindling-Pichl, Germany 
RAW 264.7 cell line American Type Culture Collection 
(ATCC), Rockville, USA 
 
Rinsing buffer pH 7.35  
  115 mM NaCl  
    25 mM NaHCO3  
   5.9 mM KCl  
 1.18 mM MgCl2  
 1.23 mM NaH2PO4  
   1.2 mM Na2SO4  
   2.5 mM CaCl2  
    20 mM Hepes  
 H2O  
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3.5.2 Culture of RAW-Macrophages 
 
The murine macrophage cell line RAW 264.7 was cultivated in DMEM containing 
10% FBS and 1% Glutamin. The cells grew in an adherent monolayer in polystyrole 
flasks in an area of 75 or 150 cm2 and were passaged once or twice per week. For 
investigations, the cells were diluted and 3 x 106 cells/ 2 ml were seeded into a 6 well 
plate und cultivated for 3 days until the experiment. 
Determination of cell concentration and viability was performed in Vi-CELLTM cell 
viability analyser (Beckman Coulter, Krefeld, Germany). 
 
3.5.3 Isolation and culture of Kupffer cells 
 
Initially, rat livers were digested by rinsing with 80 mg of Collagenase in 100 ml 
rinsing buffer. Subsequently, liver was resected and stored in 100 ml ice cold PBS. 
After gentle mincing and filtration (150 µm mesh) hepatocytes were separated from 
non parenchymal cells by centrifugation for 5 min at 50 g and 40°C. Remaining 
supernatant was centrifuged for 10 min at 500 g and the pellet was resuspended in 
40 ml medium (containing DMEM, 10% FBS, 1% glutamin and 1% Pen/Strep). The 
resulting suspension was transferred to a cell culture vessel to allow cells to adhere 
for 1 h at 37°C in an incubator. Afterwards endothelial cells were removed by adding 
7 ml of trypsin solution. Remaining Kupffer cells were washed with medium, 
suspended by scraping and centrifuged for 10 min at 500 g. Finally, 15 ml of medium 
were added; cells were resuspended and cultivated in cell culture vessels. Cultivation 
was done according to cell culture with RAW 264.7 macrophage cell line. 
 
 
 
28 3 Materials and methods 
3.6 Rat animal models 
 
6 week old male Sprague-Dawley rats weighing 190 - 220 g were purchased from 
Charles-River-laboratories (Sulzfeld, Germany) and housed in a 12 h/ 12 h day/night 
cycle with free access to food (Ssniff, Soest, Germany) and tap water. 
All animals received human care in compliance with the “Principles of Laboratory 
Animal Care”. Studies were registered and approved by the government authorities. 
 
3.6.1 Materials 
Table 4 Materials used for animal studies 
Product Company 
Fentanyl Janssen-Cilag, Neuss, Germany 
Midazolam Ratiopharm, Ulm, Germany 
Isofluran Abbott, Wiesbaden, Germany 
Carbogen (5% CO2, 95% O2) Air Liquide, Duesseldorf, Germany 
 
 
3.6.2 Biodistribution studies 
 
Animals were anesthetized by i.p. injection of 0.005 mg/kg Fentanyl and 2.0 mg/kg 
Midazolam. For further maintainance of anesthesia, 1.5% Isofluran was continuously 
conducted using a vaporizer with Carbogen (5% CO2/95% O2) as a carrier gas. To 
obtain blood pressure and supervise anesthesia, the jugular artery was cannulated 
with a 16 gauge-PE catheter and connected to a blood-pressure gauge. The abdomen 
was opened by midline-laparotomy and the portal vein was prepared. 1.0 ml buffered 
gelatin-nanoparticle-solution containing 20 nmol Alexa Fluor® 488 5`-end-labeled 
NF-κB decoy oligonucleotides or unloaded Texas Red® labeled gelatin-
nanoparticle-solution, respectively, was injected into the portal vein and organs and 
Materials and methods 29 
blood samples were withdrawn after 15 minutes. Livers were drained, rinsed free 
from blood with PBS via a peristaltic pump at a flow of 55 ml/min for 2 minutes and 
perfused with Formalin 3% in PBS for protein fixation. Additionally, unfixed pieces 
of liver, kidney, brain, heart, spleen and lung tissues were withdrawn, cut in 3 mm 
cubes, immediately snap frozen in liquid nitrogen and kept at -80°C until further 
examination. 
 
3.6.3 LPS 
 
Anesthesia was performed as described in chapter 3.6.2. The abdomen was opened 
by midline-laparatomy and the portal vein was prepared. Throughout the experiment 
the body temperature was maintained between 36.0°C and 37.0°C with a warming 
lamp. 
1.0 ml of a 20 nmol NF-κB decoy ODN nanoparticle-solution, a 20 nmol scrambled 
NF-κB decoy ODN nanoparticle-solution, unloaded “naked” nanoparticle-solution or 
solvent, respectively, were injected into the portal vein with a 1.0 ml syringe over a 
period of 5 minutes. 
15 minutes thereafter 10 µg of LPS (50 µg/ml in PBS, E.coli serotype 055:B05) was 
applied to the portal vein. Following a 30 minutes incubation period, blood and liver 
tissue samples were collected and further treated as described in chapter 3.6.2.  
After centrifugation of blood samples at 5000 U/min for 8 minutes, the plasma was 
stored in aliquots at -80°C. 
 
3.6.4 Ischemia/reperfusion injury 
 
Anesthesia was performed as described in chapter 3.6.2. The abdomen was opened 
by midline-laparotomy and the portal triad was prepared. Throughout the experiment 
the body temperature was maintained between 36.0°C and 37.0°C with a warming 
lamp. 
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The arterial and portal blood flow to the left lateral and median lobe of the liver was 
interrupted by applying an atraumatic clip, resulting in a 70% liver ischemia. After 
60 minutes of ischemia, the blood supply was restored by removal of the clip and the 
reperfusion period was initiated. 
Subsequently to the collection of blood samples into heparinized tubes, animals were 
sacrificed after 120 minutes of reperfusion by bleeding. The organ was rinsed free 
from blood by perfusing the liver with PBS through the portal vein via a peristaltic 
pump at a flow of 55 ml/min for 2 minutes. The median lobe was excised and the 
remaining lobes were perfused with formalin 3% in PBS for protein fixation. 
All tissues were cut in 3 mm cubes, immediately snap frozen in liquid nitrogen and 
kept at -80°C until further examination. 
After centrifugation of blood samples at 5000 U/min for 8 minutes, the plasma was 
stored in aliquots at -80°C. 
15 minutes prior to initiation of ischemia, 1.0 ml of a 20 nmol decoy ODN 
nanoparticle-solution, a 20 nmol scrambled decoy ODN nanoparticle-solution, 
unloaded “naked” nanoparticle-solution and solvent, respectively, were injected into 
the portal vein with a 1.0 ml syringe over a period of 5 minutes (Figure 6). 
 
n=5
Organ/blood
withdrawal
Nanoparticles
15 min 60 min Ischemia 120 min Reperfusion
 
Figure 6 Experimental setting of ischemia/reperfusion 
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3.7 Immunohistochemistry 
 
3.7.1 Materials 
Table 5 Materials used for immunohistochemistry 
Product Company 
Hoechst 33342 Invitrogen, Karlsruhe, Germany 
Permafluor® mounting medium Beckman Coulter, Krefeld, Germany 
Triton® X-100 Sigma-Aldrich, Taufkirchen, Germany 
 
3.7.2 Antibodies 
Table 6 Primary antibodies used for immunohistochemistry 
Product Company 
p65 (RB-9034) rabbit polyclonal IgG Labvision, Fremont, USA 
CD 163 (MCA342R) mouse anti-rat IgG 
AbD Serotec GmbH, Duesseldorf, 
Germany 
 
Table 7 Secondary antibodies used for immunohistochemistry 
Product Company 
Alexa Fluor® 488 goat anti-mouse IgG Invitrogen, Karlsruhe, Germany 
Alexa Fluor® 546 goat anti-rabbit IgG Invitrogen, Karlsruhe, Germany 
Alexa Fluor® 633 goat anti-mouse IgG Invitrogen, Karlsruhe, Germany 
 
3.7.3 Staining of isolated Kupffer cells 
 
At first, cover slips were placed in each well of 24-well plates. Subsequently, 
Kupffer cells acquired from isolation process (~ 0.3 x 106 cells/ml) were equally 
distributed to prepared well plates. Each well was completed with medium (DMEM 
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containing 10% of FBS and 1% of glutamin) to a total volume of 500 µl. After 1 h of 
adherence to the cover slips, cells were washed with medium once and 450 µl 
medium were added. Cells were then incubated with 50 µl of an NF-κB decoy 
ODN488 loaded fluorescent gelatin nanoparticle suspension. The final decoy ODN 
concentration per well was adjusted to 0.5 µmol/l, i.e. 3.7 µg ODN per well. The 
according nanoparticle concentration resulting from 2.5% [m/m] drug loading 
accounted for 148.4 µg gelatin nanoparticles per well. After 15 min, 1 h and 2 h 
respectively of incubation, cells were fixed with 3% formalin in PBS for 10 min and 
washed thrice with PBS. 
Subsequent to fixing and washing, Kupffer cells were permeabilized for 2 min with 
0.2% Triton® X in PBS and washed three times with PBS. Nuclear staining was then 
performed by incubating cells with 10 µl Hoechst solution (50 µg/ml) in 500 µl PBS 
for 10 min. Following final washing for three times with PBS, cover slips were taken 
from well plates and were fixed with PermaFluor® mounting medium on a 
microscopic slide. After storing over night, the Kupffer cell preparations were 
analyzed with a Zeiss LSM 510 Meta confocal laser scanning microscope (Carl Zeiss 
Microscope Systems, Jena, Germany). 
 
3.7.4 Staining of liver tissue 
 
3.7.4.1 p65 
 
Formalin-fixed, paraffin embedded liver samples were cut into 8 µm thick slices. 
After deparaffinization in xylene and rehydration through a declining ethanol-series, 
slices were stained using CoverplateTM disposable immunostaining chambers 
(Thermo Shandon, Frankfurt, Germany). For evaluation of NF-κB-activation, 
sections were first incubated with a 1:50 dilution of a rabbit polyclonal p65-antibody 
and a 1:100 dilution of a mouse anti-rat monoclonal CD 163-antibody in 0.2% saline 
buffered BSA overnight at 4°C. After repeated washing with PBS, the secondary 
antibodies Alexa® 488 goat anti-mouse and Alexa® 546 goat anti-rabbit in 0.2% 
saline buffered BSA were applied for 45 minutes, followed by staining of nuclei with 
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Hoechst for further 5 minutes. All sections were mounted with PermaFluor® 
Mounting Medium and analyzed by confocal laser scanning microscopy (Zeiss LSM 
510 Meta CLSM, Carl Zeiss Microscope Systems, Jena, Germany).  
 
3.7.4.2 Distribution of labeled nanoparticles 
 
For evaluation of decoy nanoparticle biodistribution, slices were treated accordingly 
as in section 3.7.4.1 (primary antibody mouse anti-rat monoclonal CD 163 diluted 
1:100, AbD Serotec, and secondary antibody Alexa® 488 goat anti-mouse diluted 
1:400, Invitrogen). 
 
3.7.4.3 Distribution of labeled decoy nanoparticles 
 
For evaluation of decoy nanoparticle biodistribution, slices were treated accordingly 
as in section 3.7.4.1 (primary antibody mouse anti-rat monoclonal CD 163 diluted 
1:100, AbD Serotec, and secondary antibody Alexa® 633 goat anti-mouse diluted 
1:400, Invitrogen). 
 
3.8 EMSA 
 
3.8.1 Materials and solutions 
Table 8 Materials used for electro mobility shift assay 
Product Company 
[γ32P]-ATP 3000 Ci/mmol Amersham, Freiburg, Germany 
Nuc Trap probe purification columns Stratagene, La Jolla, USA 
T4 polynucleotide kinase USB, Cleveland, USA 
Oligonucleotides Promega, Heidelberg, Germany 
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Buffer A   Buffer B  
   10 mM Hepes      pH 7.9     20 mM Hepes      pH 7.9 
   10 mM KCl   400 mM NaCl 
  0.1 mM EDTA       1 mM EDTA 
  0.1 mM EGTA    0.5 mM EGTA 
 H2O     25 % Glycerol 
add freshly before use:  add freshly before use: 
    1 mM DTT     1 mM DTT 
 0.5 mM PMSF     1 mM PMSF 
 
STE buffer  pH 7.5  Binding Buffer 5x  
   10 mM Tris     20 % Glycerol 
 100 mM NaCl      5 mM MgCl2
     1 mM EDTA   2.5 mM EDTA 
 H2O  250 mM NaCl 
     50 mM Tris-HCl 
    H2O 
 
Reaction buffer   Gel loading buffer  
      90 % Binding buffer 5x      250 mM Tris-HCl 
      10 % Gel loading buffer       0.2 % Bromphenolblue 
    2.6 mM DTT       40 % Glycerol 
 H2O   H2O 
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Non-denaturizing PAA gel  TBE 10x  
     5.3 % TBE 10x     890 mM Tris 
   15.8 % 
PAA solution 
30% 
    890 mM Boric acid 
     2.6 % Glycerol       20 mM EDTA 
   0.05 % TEMED   H2O 
   0.08 % APS    
 H2O    
 
3.8.2 Extraction of nuclear protein from RAW 264.7 macrophages 
 
RAW 264.7 macrophages were grown in 6-well plates until confluence, and 
incubated with 1 nmol decoy nanoparticles and scrambled decoy nanoparticles, 
respectively, for 3 hours. Then 2 µg LPS (100 µg/ml) were added to each well, 
leading to a final concentration of 100 ng/ml. Subsequent to a 30 minute waiting 
period, plates were put on ice and cells were washed twice with ice-cold PBS, 
scraped off in PBS with a rubber cell scraper, centrifuged for 5 minutes at 1,500 rpm 
at 4°C and resuspended in 400 µl Buffer A for 15 minutes. Then 25 µl Nonidet P-40 
was added, intensively vortexed and centrifuged (12,000 rpm, 1 minute, 4°C). The 
supernatant was discarded and the nuclear pellet was resuspended in 50 µl Buffer B 
and vortexed. After 30 minutes of continuous shaking at 4°C, the nuclear extract was 
centrifuged for 5 minutes at 12,000 rpm. The supernatant containing the nuclear 
proteins was stored in aliquots at -80°C. 
 
3.8.3 Extraction of nuclear protein from liver tissues 
 
Tissue samples (approx. 60-80 mg) were prepared with a homogenizer (Potter S, 
B. Braun Biotech) by homogenizing the probes in 600-800 µl Buffer A. After 
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centrifugation (1,000 rpm, 10 minutes, 4°C) and incubation at 4°C for 10 minutes in 
300 µl freshly added Buffer A containing 18 µl of NP-40 10 %, probes were 
centrifuged (14,000 rpm, 10 minutes, 4°C). The supernatant was removed and the 
pellet was suspended in Buffer B, following incubation at 4°C for 30 minutes under 
continuous shaking. After centrifugation (14,000 rpm, 10 minutes, 4°C) supernatants 
were frozen at -80°C and nuclear proteins were stored until further use for protein 
quantification and EMSA.  
 
3.8.4 Protein quantification 
 
Protein concentrations in isolated nuclear protein fractions were determined by the 
method of Bradford using Coomassie brilliant blue G250. Absorbance of the samples 
was measured at 590 nm (Tecan Sunrise Absorbance reader, Tecan). 
 
3.8.5 Radioactive labeling of consensus oligonucleotides 
 
Double-stranded oligonucleotides containing the consensus sequence for NF-κB 
5’- AGT TGA GGG GAC TTT CCC AGG C -3’ were 5’ end-labeled with [γ
32
P]-
ATP using the T4 polynucleotide kinase which catalyzes the transfer of the 
radioactive phosphate to the 5’ hydroxyl site of the DNA. After incubation of 
oligonucleotides with T4 kinase for 10 minutes at 37°C, the reaction was terminated 
by addition of 0.5 M EDTA solution. The radioactive labeled DNA was separated 
from unlabeled DNA by using Nuc Trap probe purification columns. Radioactive 
oligonucleotides were eluted from the column with 70 µl of STE buffer and frozen at 
-20°C until used for EMSA.  
 
3.8.6 Binding reaction and electrophoretic separation 
 
To ensure equal amounts of proteins, 30 µg (liver tissue) and 5 µg of protein (RAW 
264.7 macrophages), respectively, were provided in a total amount of 14 µl, 
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containing 2 µg poly(dIdC) and 3 µl of freshly prepared reaction buffer. Then, 
samples were incubated for 10 minutes at room temperature. To start NF-κB – DNA 
binding reaction, 1 µl of the radioactive labeled oligonucleotide was added and 
samples were left for 30 minutes at room temperature. The protein-oligonucleotide 
complexes were separated by gel electrophoresis (Mini-Protean 3, BioRad) with 
0.25 x TBE buffer at 100 V for 60 minutes using non-denaturizing polyacrylamide 
gels.  
For supershift analysis, 1 µl of an antibody against p50 or p65, respectively, was 
incubated with the nuclear protein for 30 minutes, before adding the radioactive 
labeled probe. Electrophoretic separation was done as described above. 
 
3.8.7 Detection and evaluation 
 
Following electrophoresis, gels were exposed to Cyclone Storage Phosphor Screens 
(Canberra-Packard, Schwadorf, Austria) for 24 hours, followed by analysis with a 
phosphor imager station (Cyclone Storage Phosphor System, Canberra-Packard). 
 
3.9 Real time RT-PCR 
 
3.9.1 Primers 
 
TNF-α primers and probe were obtained as a complete TaqMan® Gene Expression 
Assay (Rn99999017_m1, Applied Biosystems, Hamburg, Germany). GAPDH 
primers were designed using the Primer Express® 2.0 software program. GAPDH 
forward primer: 5'-GGG AAG GTG AAG GTC GGA GT-3'; reverse primer: 5'-TCC 
ACT TTA CCA GAG TTA AAA GCA G-3'; probe: 5'-ACC AGG CGC CCA ATA 
CGA CCA A-3'. 
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3.9.2 RNA isolation and sample preparation 
 
25 mg of liver tissue were used to isolate mRNA by using the RNeasy® Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturers` instructions. 
Homogenized tissue samples were loaded onto a QIAshredder Spin Column and 
spun down (14,000 rpm, 2 minutes, RT) to ensure complete homogenization. The 
extracts were then applied to the RNeasy® mini columns. Following several washing 
and centrifugation steps, the RNA bound to the RNEasy® Mini Spin Columns was 
eluated with RNAse free water. DNAse digestion was performed during isolation 
with RNAse-free DNAse set from Qiagen. Content of isolated RNA was determined 
by UV-spectroscopy at 260 nm/ 280 nm with a NanoDrop® ND-1000 
Spectrophotometer, NanoDrop Technologies, Wilmington, USA (kindly provided by 
the GSF – National research center for environment and health, Großhadern). 
 
3.9.3 Reverse transcription 
 
Reverse transcription was carried out using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Hamburg, Germany) in a 7300 Real-Time 
PCR System (Applied Biosystems, Hamburg, Germany). Total amount of RNA 
deployed was 1,500 ng in 30 µl of reaction buffer containing 2x RT buffer, MgCl2, 
dNTP Mix, random hexamers, RNAse inhibitor and reverse transcriptase enzyme. 
Table 9 Cycling protocol for reverse transcription into cDNA 
Purpose Temperature Time 
Primer extension 25°C 10 minutes 
cDNA synthesis 48°C 30 minutes 
Reaction termination 95°C 5 minutes 
 
 
 
Materials and methods 39 
3.9.4 Real-time PCR 
 
Real time PCR was conducted with the TaqMan® Universial Master Mix Kit in a 
7300 Real-Time PCR System (Applied Biosystems, Hamburg, Germany). In total 
100 ng of cDNA in 20 µl of reaction buffer containing 2 x Master Mix and the 
according forward and reverse primers as well as the corresponding TaqMan Probe 
was deployed. 
Table 10 Cycling protocol for real time RT-PCR analysis 
Purpose Temperature Time 
Initial denaturizing 95°C 10 minutes 
Denaturizing 95°C 15 seconds 
Annealing and extension 60°C 60 seconds 
 
 
         50 cycles 
 
3.9.5 Quantification 
 
Results were quantified based on the relative expression of the TNF-α gene versus 
the housekeeping gene GAPDH using the mathematical model for relative 
quantification according to Pfaffl (104). 
 
3.10 ELISA 
 
Rat TNF-α UltraSensitive ELISA Kit was obtained from BioSoure, Camarillo, USA. 
Determination of serum TNF-α levels was performed according to the manufacturers 
manual. Briefly, after centrifugation of heparinized blood samples for 8 minutes at 
5,000 rpm, the supernatant was separated and stored at -80°C until further analysis. 
Then 50 µl incubation buffer and 50 µl biotin conjugate were added to each 50 µl 
serum sample. Following a waiting period for 2 hours and several washing steps, the 
samples were incubated with 100 µl streptavidin coupled horse radish peroxidase for 
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30 minutes. After further washing steps, 100 µl of stabilized chromogen were added 
to each well, causing a color development proportional to the amount of rat TNF-α in 
the sample. Finally, reaction was terminated by adding 100 µl of stop solution and 
the absorbance was measured at 450 nm using the SUNRISE Absorbance Reader 
from TECAN (TECAN Deutschland GmbH, Crailsheim, Germany). 
 
3.11 Measurement of transaminases 
 
Activities of serum aminotransferases (alanine transferase (ALT) and aspartate 
transferase (AST)) were determined as established markers of hepatic injury. 
Activities of heparinized serum were kindly measured by Babett Rannefeld from the 
Institute for clinical chemistry, Klinikum Großhadern, University of Munich, 
Germany, using a serum multiple analyzer (Olympus AU 2700, Germany) at 37 °C. 
 
3.12 Gene Chip analysis 
 
Isolation of RNA, reverse transcription and the following Gene Chip analysis is 
kindly conducted by Dr. H. Blum, Dr. S. Bauersachs and A. Klanner from the 
Laboratory for Functional Genome Analysis (Lafuga). 
 
3.12.1 Isolation of RNA 
 
RNA was extracted using the RNeasy Kit (Quiagen, Hilden, Germany) and Trizol 
(Invitrogen, Karlsruhe, Germany). Liver samples weighing about 200 – 300 mg from 
each animal were added to 1 ml of pre-chilled Trizol Reagent. Total RNA extractions 
were performed according to the manufacturer’s protocol and were further purified 
by passage through RNeasy mini-columns. Final RNA preparations were 
resuspended in RNase-free water and stored at -80°C. The concentration of extracted 
Materials and methods 41 
RNA was quantified spectrophotometrically, and purity and integrity was assessed 
by agarose gel electrophoresis. All samples showed 260/280 absorbance ratios of 
approximately 2.0, and all displayed intact ribosomal 28S and 18S RNA bands in an 
ratio of about 2:1 as seen by ethidium bromide staining. 
 
3.12.2 Reverse transcription and hybridization 
 
Double-stranded cDNA was synthezised using the Affymetrix kit (Affymetrix, Santa 
Clara, USA), starting with samples of 10 µg of total RNA. An in vitro transcription 
(IVT) reaction was carried out to produce biotin-labelled cRNA from the cDNA 
according to the manufacturer’s protocol (http://www.affymetrix.com/support/ 
technical/manual/expression_manual.affx). After fragmentation of cRNA, 10 µg of 
biotin-labelled cRNA probe are hybridized with an Affymetrix GeneChip according 
to the companys standard procedure. After washing, the hybridized probe arrays are 
counterstained with streptavidin phycoerythrin conjugate and scanned with a 
Typhoon scanner (GE Healthcare, Munich, Germany). 
 
3.13 Statistical analysis 
Number of experiments is depicted in the respective figure legend. Results are shown 
as mean ± SEM. Statistical analysis was performed using the GraphPad Prism 3.03 
software (GraphPad software Inc, San Diego, USA). Significance (*) has always 
been calculated at the 95% confidence interval between indicated groups, using an 
unpaired t-test. 
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4 RESULTS 
44 4 Results 
4.1 In vitro uptake: isolated Kupffer cells 
 
We first aimed to check if gelatin nanoparticles are taken up in general by Kupffer 
cells. Therefore, Kupffer cells were isolated from rat liver to investigate phagocytosis 
of nanoparticles in vitro. To this end, gelatin nanoparticles were incorporated with a 
Texas Red X fluorescent dye and additionally loaded with Alexa® 488 fluorescent 
labeled decoys. Analysis by confocal microscopy revealed a pronounced uptake after 
15 minutes incubation time already (Figure 7). In addition, some decoys seem to be 
detached from the gelatin nanoparticles and to translocate to the nucleus, as several 
fluorescent decoy oligonucleotides could be found in the nuclear compartment 
separated from the carrier. The uptake as well as the translocation of decoys to the 
nucleus was further enhanced in a time-dependent kinetic pattern. 
 
15 minutes incubation
 
1 h incubation
 
2 h incubation
 
Figure 7 Time-dependent uptake of NF-κB decoy nanoparticles in isolated Kupffer cells. 
Stimulation and staining of Kupffer cells was performed as described in chapter 3.7.3. 
Blue: nuclei, green: decoy ODNs, red: gelatin nanoparticles. The yellow colour indicates 
colocalization of decoy ODNs and nanoparticles. 
 
Results 45 
4.2 In vivo distribution 
 
4.2.1 Gelatin nanoparticles 
 
Since a distinct uptake of gelatin nanoparticles by Kupffer cells in vitro is to be seen 
as soon as 15 minutes after the challenge, we wanted to figure out if an analogue 
uptake pattern can be observed in vivo. Therefore, a Texas Red X fluorescent dye 
was incorporated into the gelatin nanoparticles and 1.0 ml of a buffered saline 
nanoparticle-solution was injected into the portal vein. Examination of confocal 
microscope images showed a clear uptake of gelatin nanoparticles by Kupffer cells, 
whereas the surrounding parenchyma remains completely unaffected (Figure 8). 
 
Nanoparticles Kupffer cells Overlay
 
Figure 8 Gelatin nanoparticles are selectively taken up in the liver by Kupffer cells. Staining and 
confocal microscopy was performed as described in chapter 3.7.4. Red: gelatin 
nanoparticles, green: Kupffer cells. 
 
4.2.2 Decoy nanoparticles 
 
Since we showed a distinct hepatic uptake of gelatin nanoparticles by Kupffer cells, 
we aimed to test if the loaded decoy oligonucleotides are still bound stably to the 
nanoparticles under in vivo conditions. Therefore, an Alexa® 488 fluorescent dye 
was attached to the decoy oligonucleotides and the distribution of decoy loaded 
nanoparticles was evaluated. 
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4.2.2.1 Systemic distribution 
 
In our approach, decoy nanoparticles are injected intraportally, thus entering the 
systemic circulation. Although the liver is the first organ to be reached by 
administration into the portal vein, a delivery to other organs can not be ruled out. 
Therefore we wanted to investigate the whole body distribution of systemically 
applied decoy nanoparticles 15 minutes after injection. Fluorescent labeled decoy 
oligonucleotides loaded onto gelatin nanoparticles were localized to a predominant 
extent in hepatic tissue (Figure 9). Some decoy oligonucleotides were detected in the 
lung and the spleen, but kidney, heart and brain tissues were not affected at all. 
 
Brain HeartKidney
Liver Lung Spleen
 
Figure 9 Intraportal administration of decoy nanoparticles results in enhanced distribution in liver 
tissue. Staining and confocal microscopy was performed as described in chapter 3.7.4. Red: 
decoy ODNs, green: Kupffer cells and macrophages, blue: nuclei. The yellow colour 
indicates colocalization of decoy ODNs and macrophages. 
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4.2.2.2 Intrahepatic localization 
 
As the liver is the main organ affected by intraportal injection, we wanted to clarify 
in the next step if Kupffer cells are the predominant liver cell type targeted. And 
indeed, as displayed in Figure 10, a colocalization of decoys and Kupffer cells in 
vivo 15 minutes after application of gelatin nanoparticles loaded with decoy 
oligonucleotides is clearly to be seen, as indicated by the yellow colour. There were 
no decoys found in hepatocytes or endothelial cells. 
 
Decoys Kupffer Cells Nuclei Overlay
 
Figure 10 Decoy nanoparticles are selectively taken up in the liver by Kupffer cells. Staining and 
confocal microscopy was performed as described in chapter 3.7.4. Red: decoy ODNs, 
green: Kupffer cells, blue: nuclei. The yellow colour indicates colocalization of decoy 
ODNs and Kupffer cells. 
 
4.2.3 DOTAP/DOPC liposomes 
 
DOTAP/DOPC liposomes are widely used carriers for oligonucleotides. Hence, we 
wanted to compare the efficiency of the state-of-the-art liposomal delivery to our 
gelatin nanoparticulate carrier. Fluorescent labeled decoy oligonucleotides were 
incorporated into DOTAP/DOPC liposomes and administered intraportally. Analysis 
by confocal imaging (Figure 11) showed an increased loss of decoy oligonucleotides 
within the sinusoid as well as an enhanced uptake by hepatocytes and endothelial 
cells (yellow arrows) in comparison to the use of gelatin nanoparticles as 
ODN-carrier. 
Thus, gelatin nanoparticles indeed are the superior carrier for a selective targeting of 
Kupffer cells. 
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Figure 11 Use of DOTAP/DOPC liposomes as carrier for incorporated decoy ODNs results in 
increased loss of decoys as well as in enhanced delivery to many liver cell types (yellow 
arrows). Staining and confocal microscopy was performed as described in chapter 3.7.4. 
Red: decoy ODNs, green: Kupffer cells, blue: nuclei. The yellow colour indicates 
colocalization of decoy ODNs and Kupffer cells. 
 
4.3 In vitro: Decoy nanoparticles and LPS – RAW macrophages 
 
As we were able to confirm that decoy oligonucleotides are delivered to the liver 
macrophages by gelatin nanoparticles, we now aimed to test whether decoy 
nanoparticles are also able to inhibit NF-κB in vitro. To this end, a RAW 264.7 cell 
line was used as a model for a macrophage cell type and stimulated with LPS, a well 
known inducer of NF-κB binding activity. 
 
4.3.1 Composition of the NF-κB dimer in LPS challenged RAW macrophages 
 
The transcription factor NF-κB is composed of two subunits and forms either hetero- 
or homodimers. To determine the composition of the dimer after LPS challenge in 
this cell line, the nuclear proteins from RAW 264.7 macrophages stimulated with 
LPS were extracted. EMSA supershift analysis (Figure 12) revealed that the 
investigated NF-κB complex consists of the subunits p50 and p65, as the respective 
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antibody effectuates a strong decline in the radioactive signal intensity (middle and 
right lane) in comparison to the not-shifted band (left lane). 
 
+LPS + p65-antibody
+LPS + p50-antibody
++ +LPS
p50/p65
 
Figure 12 The transcription factor NF-κB is composed of the two subunits p50 and p65. Stimulation 
of RAW 264.7 macrophages, protein extraction and determination of NF-κB binding 
activity by electromobility shift assay (EMSA) was performed as described in section 3.8. 
 
4.3.2 NF-κB decoy oligonucleotides bind NF-κB 
 
The NF-κB decoy oligonucleotide sequence we wanted to apply possesses two 
NF-κB binding sites, one for p50 and the other for p65. As shown in Figure 12, the 
LPS induced NF-κB complex consists of these two subunits. To verify that the used 
NF-κB decoy oligonucleotides are able to bind to the activated NF-κB proteins, 
nuclear extracts of RAW 264.7 macrophages stimulated with LPS were incubated 
with 1.75 pmol of decoy oligonucleotides for 15 minutes. The radioactive labeled 
NF-κB binding oligonucleotides added thereafter were not able to bind to NF-κB. 
This suggests that the decoy oligonucleotides applied in an equimolar amount replace 
the radioactive labeled probe, therefore proofing the selective binding of the decoy 
oligonucleotide sequence. Scrambled decoy oligonucleotides were not able to hinder 
the radioactive labeled probe from binding the NF-κB protein as much as the binding 
decoy oligonucleotides, indicating the sequence specifity. However, a small decrease 
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in signal intensity can be observed by the use of scrambled decoy oligonucleotides. 
This can be explained by the large amount of oligonucleotides used in this 
experiment, which inevitably leads to an unselective interaction. 
+Decoy Oligonucleotide
+scrambled Decoy Oligonucleotide
++ +LPS
NF-κB-DNA complex
 
Figure 13 Addition of 1 µl of double stranded NF-κB decoy oligodeoxynucleotide hinders radioactive 
labeled NF-κB consensus oligonucleotides from binding to NF-κB. Stimulation of RAW 
264.7 macrophages, protein extraction and determination of NF-κB binding activity by 
electromobility shift assay (EMSA) was performed as described in section 3.8. 
 
4.3.3 Decoy nanoparticles reduce LPS induced NF-κB activity in vitro 
 
We determined the influence of decoy nanoparticles on NF-κB binding activity in 
vitro upon LPS stimulation by EMSA. Figure 14 displays that the elevation of 
NF-κB activity could be strongly diminished by the application of decoy 
nanoparticles before the LPS challenge. Scrambled decoy nanoparticles showed only 
a slight impact on NF-κB activity in vitro, which demonstrates that the degree of 
NF-κB inhibition is sequence dependent. As described in the section above, the 
presence of random oligonucleotides to such an extent seems to be sufficient to 
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influence NF-κB binding activity moderately. However, the use of NF-κB decoy 
oligonucleotides results in a much more prominent downregulation of NF-κB. 
 
+
+scrambled Decoy-NP
+Decoy-NP
+
+
++LPS
NF-κB-DNA complex
 
Figure 14 Addition of 1 µM decoy nanoparticles 3 h before LPS challenge reduces NF-κB binding 
activity. Stimulation of RAW 264.7 macrophages, protein extraction and determination of 
NF-κB binding activity by electromobility shift assay (EMSA) was performed as described 
in section 3.8. 
 
4.4 In vivo: Decoy nanoparticles and LPS 
 
After establishing that (i) the gelatin nanoparticles are an appropriate Kupffer cell 
targeting carrier for decoy oligonucleotides in vitro and in vivo and that (ii) 
application of decoy nanoparticles inhibits NF-κB binding activity in vitro, we next 
aimed to investigate if decoy nanoparticles display an inhibitory action in vivo as 
well. As LPS is a well-known and reliable stimulus of NF-κB activation in Kupffer 
cells, we utilized an LPS-model to supply the proof of principle for a Kupffer cell 
specific NF-κB inhibition by decoy nanoparticles.  
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4.4.1 Induction of NF-κB activity by LPS 
 
We determined the increase in NF-κB binding activity by EMSA after the challenge 
with different doses of LPS (Figure 15). As we aimed to simulate a mild 
inflammatory reaction, we decided to use a dose of 10 µg LPS for further 
experiments. This low quantity is sufficient to induce NF-κB activity without causing 
a severe sepsis. 
 
--1050200LPS (µg)
NF-κB-DNA complex
 
Figure 15 Systemic application of LPS induces hepatic NF-κB binding activity. Protein extraction and 
determination of NF-κB binding activity by electromobility shift assay (EMSA) was 
performed as described in chapter 3.8. 
 
4.4.2 Influence on NF-κB activity 
 
Intraportal administration of LPS lead to a clear increase in NF-κB binding activity 
(Figure 16). However, this induction can be completely abolished by the prior 
application of decoy nanoparticles. Scrambled decoy and naked nanoparticles, 
respectively, showed no impact on NF-κB binding activity. To ensure comparability 
between the treated groups, decoy versus scrambled decoy nanoparticles were 
compared for future experiments, as differences in obtained results have to be due to 
the sequence specifity of the decoy oligonucleotide. 
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Figure 16 Administration of NF-κB decoy nanoparticles abolishes LPS induced NF-κB binding 
activity. Protein extraction and determination of NF-κB binding activity by electromobility 
shift assay (EMSA) was performed as described in section 3.8. All experiments were 
conducted three times. One representative EMSA blot is depicted above. 
 
4.4.3 Decoy nanoparticles retain p65 within the cytoplasm 
 
We next wanted to clarify the underlying mechanism of the NF-κB inhibition by 
decoy nanoparticles. Liver tissues treated with either scrambled decoy nanoparticles 
or decoy nanoparticles before the challenge with LPS were stained with an antibody 
against p65. Confocal microscopy showed that p65 seems to be detained from 
translocation to the nucleus (Figure 17). As the transcription factor NF-κB has to 
enter the nucleus in order to bind to its designated promoter region, a retention in the 
cytoplasm makes transcription impossible. 
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Figure 17 Decoy nanoparticles prevent p65 from entering the nucleus in Kupffer cells. Staining and 
confocal microscopy was performed as described in chapter 3.7.4. Blue: nuclei,  
green: Kupffer cells, red: p65. The purple colour indicates colocalization of p65 and 
nucleis. 
 
4.4.4 Influence on TNF-α 
 
4.4.4.1 TNF-α mRNA expression 
 
The TNF-α gene is mainly regulated by the transcription factor NF-κB. Thus, a 
reduction in NF-κB activity should also lead to diminished TNF-α mRNA 
expression. To test this hypothesis we conducted a real-time RT PCR to measure 
TNF-α mRNA expression of hepatic tissue. Application of decoy nanoparticles 
indeed reduced the LPS provoked rise in TNF-α mRNA in comparison to the 
scrambled decoy nanoparticle group (Figure 18). Therefore, delivery of decoy 
oligonucleotides by gelatin nanoparticles selectively into Kupffer cells results in 
interaction with NF-κB mediated downstream pathways. Hence, we provided the 
proof of principle, as targeting of Kupffer cells with decoy nanoparticles indeed 
interferes with inflammatory signalling. 
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Figure 18 Administration of decoy nanoparticles diminishes LPS induced TNF-α mRNA expression. 
RNA isolation and real time RT-PCR were performed as described in chapter 3.9. 
Experiments were conducted five times. 
 
4.4.4.2 TNF-α release 
 
After the significant reduction of hepatic TNF-α mRNA expression by the 
intervention with decoy nanoparticles, analysis of TNF-α levels in the blood plasma 
by ELISA should provide information about the systemic TNF-α release. However, 
Figure 19 reveals that the systemic TNF-α levels were only tendencially reduced by 
decoy nanoparticles without reaching statistical significance. 
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Figure 19 Systemic TNF-α release is not affected by decoy nanoparticles. ELISA of heparinized 
blood plasma samples was performed as described in chapter 3.10. Experiments were 
conducted three times. 
 
4.5 In vivo: Decoy nanoparticles and hepatic ischemia/reperfusion 
 
As we are able to interfere with inflammatory NF-κB mediated signalling pathways 
in Kupffer cells, we now used our tool to elucidate the impact of a selective NF-κB 
inhibition in the model of hepatic ischemia/reperfusion injury. 
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4.5.1 Establishment of a rat model of partial warm ischemia/reperfusion 
 
Before we were able to investigate the impact of the decoy nanoparticles in another 
inflammatory liver setting, we had to set up a working model of warm 
ischemia/reperfusion and characterize its features. A stable anesthesia without 
affecting blood pressure or breathing rate was established using midazolam-fentanyl-
injection and isoflurane-inhalation. By placing an atraumatic clip to the Arteria 
hepatica and the portal vein, the upper lobes of the liver were completely drained 
from blood and remained entirely ischemic until the clip-removal (visual 
supervision). Upon restoration of blood supply, the blood pressure decreased about 
20 – 40 mm Hg column for 15 – 20 minutes, but recovered soon thereafter. Mucous 
obstruction of airways could be observed rarely after 2 hours reperfusion. Animal 
body temperature was controlled rectally and maintained at 36.5°C with a red light 
heating lamp. Thus, constant conditions for all animal operations could be kept to 
ensure comparability of experiments. 
 
4.5.1.1 Transaminases 
 
The degree of transaminase activity in blood plasma provides information about the 
condition of damaged liver tissue. Figure 20 and Figure 21 indicate a rise in 
transaminase levels in the reperfusion period, but not after 1 hour of ischemia. Thus, 
hepatic injury starts with the restoration of the blood supply and is augmented with 
longer reperfusion times. Sham operated animals experienced the same treatment 
regarding anesthesia and preparation as IR-groups, apart from the clamping of the 
blood stream and the subsequent disconnection of the circulation. As transaminase 
activity of sham operated animals remain at baseline level, the elevation of ALT and 
AST concentrations in the blood plasma is solely caused by ischemia and 
reperfusion. 
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Figure 20 Impact of various reperfusion times on systemic AST levels. Measurement of AST activity 
in heparinized blood plasma was performed as described in chapter 3.11. 
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Figure 21 Impact of various reperfusion times on systemic ALT levels. Measurement of ALT activity 
in heparinized blood plasma was performed as described in chapter 3.11. 
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4.5.1.2 NF-κB activity 
 
We then conducted an EMSA analysis to check if NF-κB binding activity is 
increased after postischemic reperfusion. As depicted in Figure 22, NF-κB activity is 
upregulated upon reperfusion in comparison to untreated control liver tissue. 
 
control IR 1h/2h
NF-κB-DNA complex
 
Figure 22 Ischemia/reperfusion induces NF-κB activity. Protein extraction and determination of  
NF-κB binding activity by electromobility shift assay (EMSA) was performed as described 
in section 3.8. 
 
Interestingly, sham operated animals displayed an even further elevated NF-κB 
activation (Figure 23). As a distinct liver damage of sham operated animals is not 
evident (see transaminase activities Figure 20 and Figure 21), an increase of NF-κB 
activity might not be necessarily associated with early hepatic injury. 
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Figure 23 Sham operated animals show an enhanced NF-κB binding activity. Protein extraction and 
determination of NF-κB binding activity by electromobility shift assay (EMSA) was 
performed as described in section 3.8. 
 
4.5.2 Influence of decoy nanoparticles on NF-κB activity 
 
Figure 24 shows an EMSA analysis of animals treated with nanoparticles 15 minutes 
before the initiation of the ischemic period. Again, administration of decoy 
nanoparticles reduced NF-κB binding activity to baseline levels, leading to a 
significant difference compared to the scrambled decoy nanoparticle treated group. 
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Figure 24 Administration of decoy nanoparticles reduces NF-κB binding activity induced by 
ischemia/reperfusion. Protein extraction and determination of NF-κB binding activity by 
electromobility shift assay (EMSA) was performed as described in section 3.8. All 
experiments were conducted three times. One representative EMSA blot is depicted above. 
 
4.5.3 Influence of decoy nanoparticles on TNF-α 
 
As we were able to show a significant reduction in NF-κB activation, we next 
addressed the issue of the impact on NF-κB mediated TNF-α signalling. 
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4.5.3.1 TNF-α mRNA expression 
 
Real time RT-PCR was used to determine the changes in TNF-α mRNA expression. 
As depicted in Figure 25, application of decoy nanoparticles resulted in a significant 
reduction in expression levels versus scrambled decoy nanoparticle treated animals. 
This provides the evidence that employment of decoy nanoparticles interacts with 
NF-κB downstream signalling and interferes with inflammatory pathways in Kupffer 
cells. However, uptake of gelatin nanoparticles by Kupffer cells -irrespective of the 
load- seemed to cause an elevation in TNF-α expression per se, as mRNA levels are 
raised after nanoparticle injection. 
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Figure 25 Administration of decoy nanoparticles diminishes IR induced TNF-α mRNA expression in 
comparison to the group that received scrambled decoy nanoparticles. RNA isolation and 
real time RT-PCR were performed as described in chapter 3.9. Experiments were 
conducted five times. 
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4.5.3.2 TNF-α release 
 
Unlike systemic LPS challenge, the injury caused by hepatic ischemia and 
reperfusion is primary a local event. Therefore, an intervention in the liver with 
decoy nanoparticles should entail a change in TNF-α plasma levels. ELISA 
conducted with heparinized plasma samples indeed showed a decrease in systemic 
TNF-α release after decoy nanoparticle application in comparison to scrambled 
decoy nanoparticle treatment. However, no significant differences could be seen due 
to the large deviation of measurements. 
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Figure 26 Decrease of systemic TNF-α cytokine levels by administration of decoy nanoparticles is 
statistically not significant. ELISA of heparinized blood plasma samples was performed as 
described in chapter 3.10. Experiments were conducted three times. 
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4.5.4 Influence on transaminase levels 
 
The transaminases ALT and AST (GPT and GST respectively) are commonly 
accepted as markers for liver damage. Hence, we were interested in evaluating the 
change on liver damage by determining the impact of decoy nanoparticles on 
transaminase activities in blood samples. As shown in Figure 27 and Figure 28 
respectively, transaminase levels were not affected by NF-κB-inhibition in Kupffer 
cells. 
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Figure 27 Administration of nanoparticles does not affect systemic AST levels. Measurement of AST 
activity in heparinized blood plasma was performed as described in chapter 3.11. 
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Figure 28 Administration of nanoparticles does not affect systemic ALT levels. Measurement of ALT 
activity in heparinized blood plasma was performed as described in chapter 3.11. 
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5.1 Targeting Kupffer cells with decoy nanoparticles 
 
Kupffer cells are essential for inflammatory signalling in various hepatic disorders, 
such as ischemia/reperfusion injury, chronic alcoholic liver disease and LPS 
challenge (6;7;64). Cell culture experiments with isolated hepatocytes in fact 
revealed that LPS stimulation alone is not sufficient to induce hepatocyte apoptosis, 
unless either the supernatant of cultured Kupffer cells primed with LPS is added (68) 
or a co-culture system of hepatocytes and Kupffer cells is employed (67). Thus, 
inhibition of Kupffer cell activation is of great therapeutic interest. Along this line, 
the depletion of Kupffer cells by gadolinium chloride ameliorates the outcome of 
ischemia/reperfusion (76) or endotoxin challenge (66). 
However, Kupffer cell depletion is not a clinically applicable method for various 
reasons: firstly, macrophage depletion by gadolinium chloride administration has to 
be initiated at least 24 h before the expected inflammatory injury, which is 
impractical in clinical situations. Secondly, as Kupffer cells are indispensable for a 
successful pathogen defense system, the complete loss of liver macrophages leads to 
a diminished immune response and enhanced susceptibility to pathogens (105;106). 
Therefore, finding ways for transient intervention into Kupffer cell mediated 
inflammatory pathways is a more promising approach. Utilizing NF-κB decoy loaded 
gelatin nanoparticles focuses directly on targeting Kupffer cell inflammatory 
signalling rather than whole cell destruction. 
Activation of NF-κB in Kupffer cells is a central event in liver inflammation (17) and 
plays an important role in a multitude of pathological incidents, such as 
ischemia/reperfusion (38), chronic alcoholic liver disease (107), and LPS challenge 
(69;108). Several studies presented different approaches to interact with NF-κB 
signalling by using pharmacological drugs, natural products or by an overexpression 
of IκB (36;87;109). However, the special and dual role of NF-κB in the liver has to 
be taken into account. For example, p65-knockout mice die during embryogenesis 
due to massive hepatocyte apoptosis (31) and hepatocyte-specific NF-κB inhibition 
aggravates TNF-α provoked cell death (110). In contrast, downregulation of NF-κB 
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in isolated Kupffer cells leads to a decrease in the production of cytokines and 
adhesion molecules (27;108). Therefore, finding tools for an exclusive Kupffer cell 
specific NF-κB inhibition is of obvious importance. 
To achieve such a selective Kupffer cell targeting, we used gelatin nanoparticles as a 
carrier for NF-κB inhibiting decoy oligonucleotides. In preliminary in vitro 
experiments we could prove that the decoy nanoparticles are taken up by isolated 
Kupffer cells as early as 15 minutes after the start of incubation. Moreover, we were 
able to confirm an explicit uptake of our nanoparticulate carrier in vivo by Kupffer 
cells and not by hepatocytes or other non-parenchymal cell types (Figure 8), 
providing the basis for Kupffer cell specific targeting. It is well known that upon 
intravenous administration, nanoparticles are rapidly cleared from the blood stream 
through phagocytosis, generally by macrophages of the reticuloendothelial system 
(RES) in liver and spleen (55). By labelling the decoy oligonucleotides with a 
fluorescent dye, we could demonstrate that the decoys are concomitantly transported 
to the Kupffer cells and are not detached under physiological in vivo conditions 
(Figure 9, Figure 10).  
The groups of Ogushi and Higuchi respectively employed modified liposomal 
carriers (hemagglutinating virus of Japan (HVJ-) liposomes as well as mannosylated 
cationic liposomes) to deliver decoy oligonucleotides to Kupffer cells (69;70). 
Indeed, both groups detected a diminished inflammatory cytokine release upon LPS 
challenge. However, although liposomes are mainly taken up by Kupffer cells, the 
delivery to hepatocytes to some extent can not be ruled out, as liposomes display a 
flexible form and therefore have the ability to reach the parenchyma through the 
endothelial fenestrae (58;111;112). Solid, inflexible gelatin nanoparticles feature a 
defined particle size distribution in the range of 260 to 280 nm, and are thus too large 
to pass through between endothelial cells. Therefore, the uptake of gelatin 
nanoparticles by hepatocytes is almost impossible, as the parenchyma is not 
accessible for nanoparticulate constructs. In fact, we have shown that administration 
of decoy oligonucleotides encapsulated in DOTAP/DOPC liposomes results in a 
considerable loss of decoy oligonucleotides within the sinusoid along with an 
enhanced uptake by hepatocytes and endothelial cells in comparison to decoy loaded 
gelatin nanoparticles (Figure 11). 
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In summary, by utilizing gelatin nanoparticles we developed a new technical 
perspective to target Kupffer cells selectively with decoy oligonucleotides. 
 
5.2 Impact of decoy nanoparticles on LPS challenge 
 
Besides the specific uptake of our construct in Kupffer cells, it was pivotal that 
NF-κB decoy oligonucleotides carried by gelatin nanoparticles are in fact 
biologically active. To this end, RAW 264.7 macrophages were preincubated with 
NF-κB decoy nanoparticles before LPS challenge in vitro. Indeed, we found a 
reduction in LPS induced NF-κB DNA binding activity (Figure 14). We also 
examined the impact of decoy nanoparticles on LPS provoked activation of NF-κB in 
vivo and observed a likewise inhibition of NF-κB binding to DNA (Figure 16).  
Translocation of NF-κB to the nucleus is a prerequisite for transcriptional function. 
Application of NF-κB decoy nanoparticle however seems to retain activated NF-κB 
in the cytoplasm, thereby preventing the access of the transcription factor to the 
nuclear promoter region (Figure 17). This data is in accordance with the work of 
Higuchi et al. 2005 (113), which showed an impeded translocation of NF-κB after 
NF-κB decoy administration in RAW 264.7 macrophages. However, there are also 
reports indicating that a cytoplasmatic distribution of AP-1 and NF-κB decoy 
oligonucleotides respectively might not be sufficient for the inhibition of the 
transcriptional activation of the respective transcription factors (114;115). 
To confirm that our NF-κB decoy nanoparticles in fact inhibit NF-κB driven 
transcription, we measured the expression of the TNF-α gene, as Kupffer cells are 
the major source for the production and the release of TNF-α in the liver. The 
proinflammatory cytokine TNF-α represents a well recognized target of NF-κB 
activation, as the promoter region of the TNF-α gene possesses at least three binding 
sites for NF-κB (29). Administration of decoy nanoparticles prior to LPS challenge 
significantly decreased the hepatic TNF-α mRNA expression (Figure 18). This 
provides the proof of principle for our approach, as decoy nanoparticles interfere 
with NF-κB mediated downstream signalling in Kupffer cells.  
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Besides NF-κB, other transcription factors like activator protein 1 (AP-1), cAMP 
response element-binding protein (CREB) and early growth response factor 1 (Egr-1) 
possess matching binding sequences within the promoter region of the TNF-α gene 
(29). This could explain the observation that TNF-α mRNA expression is not fully 
abolished after decoy nanoparticle treatment in comparison to the complete reduction 
in NF-κB activity seen by EMSA analysis. 
It has to be noted that TNF-α protein levels measured in blood plasma by ELISA 
remained unchanged (Figure 19). As intraportal LPS administration is a systemic 
challenge, other organs like spleen and kidney might contribute to the release of 
TNF-α (116). Thus, intervention with a Kupffer cell exclusive NF-κB blockade 
seems to have no influence on increased TNF-α levels, which originate from such a 
comprehensive stimulus. Moreover, the time interval between the application of the 
decoy nanoparticles and the actual measurement might be too short for detecting 
alterations in protein expression, as decoy treatment intervenes at the transcriptional 
stage. TNF-α levels however are not only regulated by transcription, but also by the 
release of preformed TNF-α. 
In addition to a use as a mere experimental tool, application of decoy nanoparticles 
might emerge as a further option for the treatment of septic patients. NF-κB activity 
is markedly increased in patients with septic shock, and the degree of NF-κB activity 
correlates with the severity of the disease (117). Several approaches for inhibiting 
NF-κB and preventing inflammatory signalling cascades have been investigated so 
far. IκB as the regulatory switch for NF-κB translocation presents an apparent target 
and gene transfer strategy by the overexpression of IκB-α has been shown to have a 
beneficial effect (38). However, feasibility, safety and efficacy of this approach still 
remain key problems. Other NF-κB inhibitors include NSAIDs, small molecules and 
natural products (36;87;109). Yet miscellaneous secondary effects and non-specific 
interactions display limitations for this approach. Experiments with knock-out mice 
have tried to shed light on the role of NF-κB (118). These approaches, however, are 
time-consuming and difficult to accomplish and therefore not relevant for clinical 
applications.  
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Decoy nanoparticles in contrast have to be administered just a short time period 
beforehand, which presents a major advantage for their use. By the selective mode of 
inhibition of decoy oligonucleotides, unintended interactions with other proteins 
beside NF-κB can be excluded. Therefore, application of decoy nanoparticles in the 
initial period of sepsis could be considered as an additional alternative. 
 
5.3 Impact of decoy nanoparticles on hepatic IR injury 
 
Many proteins involved in aggravation of IR injury, like TNF-α, IL-1, CINC, 
ICAM-1 and others are strongly regulated by NF-κB mediated gene transcription. 
However, signalling cascades in hepatic ischemia/reperfusion are complex, and the 
role of NF-κB in this context is poorly understood. 
Investigations on transgenic mice are the most common approach to elucidate the 
role of NF-κB in the liver and to provide a better understanding of hepatic NF-κB 
signalling. As mentioned above, p65 knock-out mice are not capable of surviving, 
emphasizing the importance of the RelA subunit (31). Mice deficient of the p50 
subunit on the other hand show normal embryonic development with minor 
deficiencies in the immune response. If these mice are subjected to hepatic 
ischemia/reperfusion (119) or partial hepatectomy (120), no differences in the extent 
of damage can be found in comparison to wild-type animals. As IκBα is an important 
regulatory trigger, it provides an obvious target for inhibition of NF-κB by 
transfection with an overexpressed degradation-resistant form of IκBα. Using an 
adenoviral construct for delivery of this superrepressor to liver cells, Uesugi et al. 
(121) showed that chronic ethanol challenge, normally leading to NF-κB activation 
and thus to liver damage, could be diminished. This leads to the assumption, that 
overall inhibition of NF-κB in the liver is beneficial in this context. Hepatocyte-
specific overexpression of a degradation-resistant form of IκBα however 
demonstrates a different view, as these animals are more susceptible to bacterial 
infections (122) and are more likely to undergo hepatocyte apoptosis after TNF-α 
treatment (110). 
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Another even more controversial picture is arising if the model of hepatic partial 
hepatectomy is applied. Iimuro et al. (34) detected an increased apoptosis of 
parenchymal cells after superrepressor delivery to the liver cells. Although most cells 
affected by this transfection were indeed hepatocytes, a small amount of Kupffer 
cells was targeted as well. This might explain the contradictory results presented by 
Chaisson et al. (110), as here hepatocyte-specific overexpression of IκBα is not 
connected with increased hepatocyte apoptosis or diminished proliferation upon 
partial hepatectomy. These data present first evidence for the importance of a 
cell-specific examination, as inhibition of NF-κB in Kupffer cells even to a minor 
extent seems to divert the hepatic fate to a different outcome. 
IκBα is activated by the upstream kinase complex of IKK1 and 2 plus the regulatory 
unit NEMO. Therefore, deletion of these kinases results in an abolishment of NF-κB 
activation. As IKK1, IKK2 or NEMO constitutive knock-out mice die during 
embryogenesis or soon after birth (123), conditional hepatocyte-specific ablation of 
IKK2 or NEMO do not impair animal survival (88). Elimination of NEMO caused a 
complete block of NF-κB activation and increased hepatocyte apoptosis after TNF-α 
challenge. Hepatocyte IKK2 deletion however did not interfere with the degree of 
NF-κB activation. As a consequence, TNF-α treatment after IKK2 elimination could 
not initiate parenchymal cell death, but strikingly protected from hepatic 
ischemia/reperfusion injury. This prompts the assumption, that IKK2 has various 
functions in hepatocytes, depending on the mode of activation. A recent study by 
Dajani et al. (124) used an adenoviral construct to inhibit IKK2 in the liver. Here, the 
blockade of NF-κB activation by deletion of IKK2 led to diminished 
proinflammatory cytokine levels and increased survival upon LPS challenge. These 
results are in contrast to those discovered by Luedde et al. (88), who could not detect 
any improvement by the deletion of IKK2 in their conditional knock-out mouse. 
However, an adenoviral approach targets all liver cells, including Kupffer cells. 
Hence, downregulation of NF-κB in Kupffer cells might be the actual trigger, 
responsible for the reduced cytokine production in this model. 
Another specific sight on the different roles of NF-κB in particular liver cell types is 
presented by Maeda et al. (125). Again, a mouse model with an IKK2 hepatocyte 
specific deletion was used to investigate diethylnitrosamine (DEN) induced 
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hepatocarcinogenesis. Surprisingly, inhibition of IKK2 in parenchymal cells (which 
actually means elimination of an antiapoptotic survival signal) promoted an increase 
in tumor size and progression, possibly by a compensatory proliferation of surviving 
hepatocytes. As an additional inhibition of IKK2 in Kupffer cells was able to reverse 
the carcinogenic effects, NF-κB in Kupffer cells seems to be responsible for 
releasing tumor-inducing agents that in turn prime hepatocytes for unregulated 
proliferation.  
These data demonstrate that NF-κB regulation in the liver turns out to be a fine 
balanced process at multiple levels, which strongly depends on the cell type looked 
at. However, all obtained data were gained by the comparison of a NF-κB knock-out 
in all liver cells versus hepatocyte-specific deletion. Selective inhibition of NF-κB 
exclusively in Kupffer cells without involvement of hepatocytes has not been 
regarded so far due to technical impossibility. Herein, our study should provide new 
insights, as we favour a Kupffer cell targeting approach. 
Recently, a report by the group of Lentsch (91) shed some light into the NF-κB 
controversy. In their model of warm IR, a slight decrease in the body temperature 
leading to hypothermia during ischemia caused an amelioration of hepatic injury. 
Amazingly, this correlated with an increase of NF-κB activity in whole liver 
homogenates. When normothermic controls were examined, the rise in NF-κB 
activity was diminished. Cell type specific differences could be evaluated by 
isolation of parenchymal and non-parenchymal cells. While NF-κB in hepatocytes 
was strongly activated during hypothermia and almost not present in normothermic 
controls, Kupffer cells showed an inverse activation scheme. Normothermic controls 
suffering from stronger liver damage showed a prominent NF-κB activation in 
Kupffer cells, but not in hepatocytes. Therefore it can be concluded, that macrophage 
NF-κB seems to be responsible for mediating IR injury. However, this study relies 
rather on isolated cells than on in vivo conditions, which allows only a limited 
transfer to the animal models. 
Ischemia/reperfusion causes a time-dependent rise of ALT and AST levels in blood 
plasma (Figure 20), as the hepatocyte cell membrane gets more porous upon liver 
damage. Inhibition of NF-κB by application of decoy nanoparticles however did not 
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cause a reduction in the transaminase release (Figure 27). These results might 
indicate that upregulation of NF-κB activity in Kupffer cells is not necessarily linked 
to an acutely higher damage. 
This is in accordance with our EMSA analysis of sham-operated animals, as 
increased NF-κB activation is found there in line with low transaminase activity at 
baseline levels (Figure 23). This increase might result from upregulation of 
protective NF-κB in hepatocytes due to anesthesia and surgery alone, counteracting a 
potential threat. Not many reports on the field of warm IR actually determine the 
degree of NF-κB activation in sham-operated controls, indicating that the 
interpretation of the obtained results might be problematic. Interestingly, few groups 
also showed a remarkable increase in sham NF-κB activity (87;91;126). Yet, many 
studies claimed a connection between elevated NF-κB activity and raised 
transaminase levels. However, reports that implicated a detrimental role of NF-κB in 
liver ischemia/reperfusion injury, acquired data by applying different medication that 
reduced the hepatic damage (86;127-129). Along this line, a concomitant reduction 
in NF-κB activity could be seen. A cell type specific examination and reflection 
however was hardly conducted. This could lead to misinterpretations, as the source 
of the increase in NF-κB activity can not be determined. A rise in NF-κB activity in 
hepatocytes is thought to protect the liver cells from external harmful events and 
signals. If the NF-κB inhibition is mainly achieved in Kupffer cells, then less 
damaging cytokines are released, thus diminishing the need of hepatocytes to 
compensate the damaging stimulus by activating NF-κB. This might prompt the 
interpretation that diminished NF-κB levels in the entire liver correlate with a 
protective effect and diminished transaminase levels. Above all, every 
pharmacological intervention could also primarily result in attenuation of ROS 
production. Any detected reduction of NF-κB levels therefore are just secondary 
effects among others, as decreased ROS release affects multiple different signalling 
cascades besides NF-κB. 
Hence, these controversial data can only be clarified by the use of an exclusive, well-
defined inhibitor that is able to interact with NF-κB without affecting other proteins. 
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We were able to demonstrate that NF-κB decoy oligonucleotides interact specifically 
with NF-κB (Figure 13), as decoy oligonucleotides mixed with active NF-κB 
prohibits binding of the transcription factor to other consensus-sequence containing 
DNA-strands. Administration of decoy nanoparticles prior to ischemia reduced 
NF-κB binding activity as well as TNF-α mRNA expression. It has to be noted that 
the injection of gelatin nanoparticles itselve (loaded or unloaded) seems to provoke 
an increase in TNF-α mRNA expression and release. The nanoparticles are probably 
taken up by Kupffer cells through phagocytosis. Challenging Kupffer cells with 
nanoparticles causes an inflammatory response, in fact by the ingestion procedure 
itself (54). Production of TNF-α is a common response by Kupffer cells after 
phagocytosis of external material (like bacteria), as secretion of cytokines is a major 
mechanism in host defense. This might explain the increased TNF-α levels after 
nanoparticle administration, as the Kupffer cells react on this stimulation the way 
they are proposed to do. 
As most reports rely on whole liver homogenates, changes of NF-κB levels in 
Kupffer cells could remain undetected due to the predominant mass of hepatocytes. 
Unfortunately, we were not able to illuminate the cell type, which is prompted by IR 
to enhance NF-κB activity. However, our results reveal that a selective inhibition in 
Kupffer cells diminishes NF-κB levels of the entire liver. Hence, it can be concluded 
that either Kupffer cells are the primary source of NF-κB in this setting, or that 
hepatocyte derived NF-κB is only upregulated in response to NF-κB dependent 
signals originated from Kupffer cells. 
 
5.4 Outlook 
 
An abolishment of NF-κB activity in the liver is expected to massively change 
hepatic transcription. And indeed, we were able to show a significant reduction in 
TNF-α mRNA expression levels. To screen other possible targets, a genechip 
analysis is currently conducted in cooperation with the Laboratory for Functional 
Genome Analysis (Lafuga, Großhadern, Germany). Using the whole rat genome 
Discussion 77 
GeneChip 230 2.0 by Affymetrix®, the obtained results should provide interesting 
insights into the altered gene expression pattern by the inhibition of NF-κB in 
Kupffer cells during hepatic ischemia/reperfusion. 
Besides potential therapeutical implications in inflammatory liver processes, decoy 
nanoparticles are a helpful tool to decipher the pleiotropic and cell specific role of 
NF-κB and its impact on the entire hepatic transcellular signalling system. For 
instance, an application of decoy nanoparticles promises to be of special interest in 
diethylnitrosamine (DEN) induced hepatocarcinogenesis, where NF-κB is transiently 
elevated in Kupffer cells (125;130).  
In addition to sepsis, elevated NF-κB levels in Kupffer cells are also found during 
alcoholic hepatitis (131) and liver fibrosis (132), which might present further 
attractive targets for an intervention with NF-κB decoy nanoparticles. 
During liver transplantation proceedings, the extracted organ is stored at a 
temperature of 4°C throughout the transportation interval in order to reduce the 
metabolic rate and to minimize tissue damage. After this cold ischemic period, non-
parenchymal cells like Kupffer cells are thought to be activated to a larger extent 
than in our model of warm ischemia/reperfusion (71). Hence, the use of Kupffer cell 
targeting decoy nanoparticles should be of great interest in this context. Liver 
transplantations can be simulated by applying the model of the isolated perfused rat 
liver, and further investigations are currently conducted in our group to evaluate the 
impact of decoy nanoparticles on reperfusion injury provoked by prolonged cold 
ischemia. In addition, working in an isolated model with a blood free environment 
provides the advantage that interaction of liver cells can be analysed exclusively, 
without the involvement of non-hepatic cell types. 
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In this present study we established a new approach to target Kupffer cells with 
decoy oligonucleotides. 
 
Initially, we validated that gelatin nanoparticles are an appropriate carrier to deliver 
NF-κB decoy oligonucleotides to the resident liver macrophages. Distribution studies 
demonstrated that decoy nanoparticles are taken up selectively into Kupffer cells 
upon intraportal injection, whereas hepatocytes remained completely unaffected. 
 
The proof of principle was provided in a LPS model. The LPS induced upregulation 
of NF-κB activity could be diminished after administration of decoy nanoparticles. 
Furthermore, the subsequent increase in TNF-α mRNA expression was also 
significantly reduced, thus proving the feasibility of our approach. 
 
After establishing a rat model of hepatic partial warm ischemia/reperfusion, we were 
able to show that an elevation of NF-κB activity caused by ischemia/reperfusion was 
strongly reduced by the application of decoy nanoparticles. Concomitantly, a 
decrease in TNF-α mRNA levels could be seen. A following Gene Chip analysis 
should provide additional targets affected by this intervention. 
 
In summary, intraportal injection of decoy nanoparticles prior to LPS challenge or 
hepatic ischemia/reperfusion abolished induction of NF-κB as well as a subsequent 
TNF-α mRNA expression (Figure 29). Kupffer cells were the only liver cells 
affected by administration of decoy nanoparticles. Hence, the downregulation of 
NF-κB in the entire liver has to originate from the resident liver macrophages, 
whereas hepatocytes are only secondary involved in this effect. The overall changes 
in liver signalling provoked by this selective NF-κB inhibition remain to be further 
investigated. This will help to decipher the impact of NF-κB on hepatic 
ischemia/reperfusion injury, which is still elusive and not at all clarified. 
 
Summary 81 
 
NF-κB
Decoy
TNF-α
Ischemia/reperfusion
Inflammation
Kupffer cells
?
Gene Chip
 
Figure 29  Summary 
 
Alex Lentsch (133) wrote a comment in Hepatology on the work of Luedde et al. 
(88) concerning the role of IKK2 in hepatic ischemia/reperfusion. He concluded that 
“NF-κB in Kupffer cells is presumed to be largely responsible for the wave of 
proinflammatory cytokines released, … although this contention has never been 
rigorously tested.” In this work we present NF-κB decoy nanoparticles as a capable 
tool, that enables us to interfere selectively with NF-κB in Kupffer cells and that 
gives us the opportunity, to further elucidate the role of this transcription factor in 
various settings like ischemia/reperfusion injury or LPS/N-galactosamine induced 
liver injury. 
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8 APPENDIX 
 
 
8.1 Abbreviations 
 
ALT   alanine amino transferase 
ANP   atrial natriuretic peptide 
AP-1   activator protein 1 
AST   aspartate amino transferase 
BSA   bovine serum albumin 
cAMP   cyclic adenosine-5’-monophosphate 
CINC   cytokine-induced neutrophil chemoattractant 
CLSM   confocal laser scanning microscopy 
COX   cyclooxygenase 
CREB   cAMP response element-binding protein 
DEN   diethylnitrosamine 
DMEM  Dulbecco´s modified eagle medium 
DNA   desoxyribonucleic acid 
DOPC   dioleoyl-glycero-3-phosphocholine 
DOTAP  dioleoyl-trimethylammonium-propane 
DTT   dithiothreitol 
EDC   ethyl-(dimethylaminopropyl)carbodiimide hydrochloride 
Egr-1   early growth response factor 1 
EMSA   electrophoretic mobility shift assay 
eNOS/iNOS  endothelial/inducible NO synthetase 
FBS   fetal bovine serum 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
Appendix 99 
HAT   histone acetyltransferase 
HDAC   histone deacetylase 
HVJ   hemagglutinating virus of Japan 
ICAM   intercellular adhesion molecule 
IKK   IκB kinase 
IL   interleukin 
IP   ischemic preconditioning 
IR   ischemia/reperfusion 
IRAK   interleukin-1 associated kinase 
IκB   inhibitory protein κB 
LBP   LPS binding protein 
LPS   lipopolysaccharide 
MCP   monocyte chemoattractant protein 
MIP   macrophage inflammatory protein 
mRNA  messenger ribonucleic acid 
NAC   N-acetylcysteine 
NEMO  nuclear factor κB essential modulator 
NF-κB   nuclear factor κB 
NP   nanoparticle 
NP-40   non-ident P 40 
NSAID  non-steroidal anti-inflammatory drugs 
ODN   oligodeoxynucleotide 
PBS   phosphate buffered saline 
PDTC   pyrrolidinedithiocarbamate 
PE   polyethylene 
 
PMSF   phenylmethylsulfonylfluoride 
PTO   phosphorothioate 
ROS   reactive oxygen species 
RT-PCR  reverse transcription polymerase chain reaction 
TGF   transforming growth factor 
TLR   toll-like receptor 
TNF-α   tumor necrosis factor-α 
TRAF   TNF-receptor associated factor 
UW   University of Wisconsin solution 
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8.2 Alphabetical list of companies 
 
Abbott       Wiesbaden, Germany 
Air Liquide      Duesseldorf, Germany 
Amersham      Freiburg, Germany 
Applied Biosystems     Hamburg, Germany 
ATCC       Rockville, USA 
Beckman Coulter     Krefeld, Germany 
Biomers.net      Ulm, Germany 
Biosource      Camarillo, USA 
Cambrex Profarmaco     Landen, Belgium 
Charles-River Laboratories    Sulzfeld, Germany 
GraphPad Software     San Diego, USA 
Invitrogen      Karlsruhe, Germany 
Janssen-Cilag      Neuss, Germany 
Labvision      Fremont, USA 
PAA Laboratories     Linz, Austria 
Peske       Aindling-Pichl, Germany 
Promega      Heidelberg, Germany 
Qiagen      Hilden, Germany 
Ratiopharm      Ulm, Germany 
Roche Diagnostics     Mannheim, Germany 
Serotec      Duesseldorf, Germany 
Sigma-Aldrich     Taufkirchen, Germany 
 
Ssniff       Soest, Germany 
Stratagene      LaJolla, USA 
Thermo Shandon     Frankfurt, Germany 
USB       Cleveland, USA 
VWR       Ismaning, Germany 
Zeiss       Jena, Germany 
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8.3 Publications 
 
8.3.1 Original Publications 
 
Hoffmann F, Zillies J, Zahler S, Coester C, Winter G, Vollmar AM.  
NF-κB Decoy Oligonucleotides loaded Gelatin Nanoparticles – a Tool for selective 
Inhibition of NF-κB in activated Kupffer cells in vivo. Gene Therapy. 2007 
submitted. 
 
Plesnila N, Baumgarten L, Retiounskaia M, Engel D, Zimmermann R, Hoffmann F, 
Landshamer S, Culmsee C.  
Delayed Neuronal Death after Brain Trauma involves p53-dependent Inhibition of 
NF-κB Transcriptional Activity. Cell Death and Differentiation. 2007 in press. 
 
Zischka H, Larochette N, Hoffmann F, Hamöller D, Jägemann N, Lichtmannegger J, 
Jennen L, Goettlicher M, Vollmar AM, Kroemer G. 
Mitochondria at the point of no return: Differential Analysis of the Permeability 
Transition by Free Flow Electrophoresis. 2007 in preparation 
 
 
 
 
 
8.3.2 Oral presentations 
 
Hoffmann F, Zillies J, Zahler S, Coester C, Winter G, Vollmar AM 
Targeting NF-κB selectively in Kupffer cells with NF-κB decoy 
oligodeoxynucleotides is a promising tool for influencing inflammatory liver 
signalling. 
48th Spring Meeting of the Deutsche Gesellschaft für experimentelle und klinische 
Pharmakologie und Toxikologie, March 13-15, 2007, Mainz, Germany. 
Naunyn Schmiedeberg´s Arch Pharmacol. 2007; 375 Suppl1: R51 
Appendix 105 
8.4 Curriculum vitae 
 
 
Persönliche Daten 
Name:     Florian Hoffmann 
Geburtstag und –ort:   08. August 1974, München 
Staatsangehörigkeiten:  deutsch, österreichisch 
Familienstand:   ledig 
 
 
Promotion 
08/2003 – 06/2007 Department of Pharmacy, Center of Drug 
Research, Pharmaceutical Biology, Prof. Dr. A. 
M. Vollmar 
 
 
Hochschule 
1994 - 2001  Studium der Pharmazie an der Universität Innsbruck, 
Österreich 
02 – 09/1995  Auslandsstudium an der University of Queensland, 
Brisbane, Australien 
21.10.1997 Erste Diplomprüfung 
10/1999 – 03/2000 Diplomarbeit am Institut für Pharmakognosie, 
Universität Innsbruck, Österreich 
18.12.2001 Zweite Diplomprüfung 
 
 
 
Schule 
1981 – 1994 Grundschule Wörth am Main, Hermann-Staudinger-
Gymnasium Erlenbach am Main, Deutschland 
 Abschluss: Abitur 
 
 
Berufsausbildung 
02/2002 – 08/2002 Pharmaziepraktikum in der Löwenapotheke, Bamberg, 
Deutschland 
08/2002 – 02/2003 Pharmaziepraktikum bei Dr. Robert Pfleger GmbH, 
Bamberg, Deutschland 
 
Appendix 107 
8.5 Acknowledgements 
 
First and above all, I am very grateful to Prof. Dr. Angelika M. Vollmar for giving 
me the chance to perform this project in her working group. Her enthusiasm and 
never-ending optimism made this work possible in the first place. Prof. Vollmar 
always believed in me and my skills and supported me at all times, unregarded how 
hopeless it seemed. 
I further want to express my gratitude to PD Dr. Stefan Zahler. His endless calmness, 
his always useful advice and his extraordinary sense of humor provided a strong 
basis for fulfilling this project. 
Sincere thanks are given to all members of my thesis committee, especially to Prof. 
Dr. Gerhard Winter for acting as co-referee. 
I am very grateful to all members of the Pharmaceutical Technology Department 
(Prof. Dr. G. Winter, Dr. C. Coester and Dr. Jan Zillies) for the steady and easy 
supply of decoy nanoparticles. And Jan, thank you for all the endless hours of 
discussion, laughter and mutual encouragement. 
Special thanks go to Dr. Grützner for introducing me into the world of small animal 
surgery. 
I am indebted to all former and present members of my lab, for providing such an 
enjoyable ambience, and for taking me as I am, even in the hardest times. Moreover, 
I want to thank my fellow PhD students, who shared my fate and who were always 
caring and supportive. 
I am very thankful that I have been given such an exceptional familiy, which suffered 
and laughed with me, which encouraged and advised me in all my plans, no matter of 
what concern. 
And Ruth, meeting you during my time here made me realize that everything I have 
done in my life up to now turned out to be right. 
 
